Hubbry Logo
Urinary tract infectionUrinary tract infectionMain
Open search
Urinary tract infection
Community hub
Urinary tract infection
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Urinary tract infection
Urinary tract infection
Urinary tract infection
View on Wikipedia
from Wikipedia

Urinary tract infection
Other namesAcute cystitis, simple cystitis, bladder infection, symptomatic bacteriuria
Multiple white cells seen in the urine of a person with a urinary tract infection using microscopy
SpecialtyInfectious disease Urology
SymptomsPain with urination, frequent urination, feeling the need to urinate despite having an empty bladder[1]
CausesMost often E. coli bacteria[2]
Risk factorsCatheterisation (foley catheter), female anatomy, sexual intercourse, diabetes, obesity, family history[2]
Diagnostic methodBased on symptoms, urine culture[3][4]
Differential diagnosisVulvovaginitis, urethritis, pelvic inflammatory disease, interstitial cystitis,[5] kidney stone disease[6]
TreatmentAntibiotics (nitrofurantoin or trimethoprim/sulfamethoxazole)[7]
Frequency152 million (2015)[8]
Deaths196,500 (2015)[9]

A urinary tract infection (UTI) is an infection that affects a part of the urinary tract.[1] Lower urinary tract infections may involve the bladder (cystitis) or urethra (urethritis) while upper urinary tract infections affect the kidney (pyelonephritis).[10] Symptoms from a lower urinary tract infection include suprapubic pain, painful urination, frequency and urgency of urination despite having an empty bladder.[1] Symptoms of a kidney infection, on the other hand, are more systemic and include fever or flank pain usually in addition to the symptoms of a lower UTI.[10] Rarely, the urine may appear bloody.[7] Symptoms may be vague or non-specific at the extremities of age (i.e. in patients who are very young or old).[1][11]

The most common cause of infection is E. coli, though other bacteria or fungi may sometimes be the cause.[2] Risk factors include female anatomy, sexual intercourse, diabetes, obesity, catheterisation, and family history.[2] Although sexual intercourse is a risk factor, UTIs are not classified as sexually transmitted infections (STIs).[12] Pyelonephritis usually occurs due to an ascending bladder infection but may also result from a blood-borne bacterial infection.[13] Diagnosis in young healthy women can be based on symptoms alone.[4] In those with vague symptoms, diagnosis can be difficult because bacteria may be present without there being an infection.[14] In complicated cases or if treatment fails, a urine culture may be useful.[3]

In uncomplicated cases, UTIs are treated with a short course of antibiotics such as nitrofurantoin or trimethoprim/sulfamethoxazole.[7] Resistance to many of the antibiotics used to treat this condition is increasing.[1] In complicated cases, a longer course or intravenous antibiotics may be needed.[7] If symptoms do not improve in two or three days, further diagnostic testing may be needed.[3] Phenazopyridine may help with symptoms.[1] In those who have bacteria or white blood cells in their urine but have no symptoms, antibiotics are generally not needed,[15] unless they are pregnant.[16] In those with frequent infections, a short course of antibiotics may be taken as soon as symptoms begin or long-term antibiotics may be used as a preventive measure.[17]

About 150 million people develop a urinary tract infection in a given year.[2] They are more common in women than men, but similar between anatomies while carrying indwelling catheters.[7][18][clarification needed] In women, they are the most common form of bacterial infection.[19] Up to 10% of women have a urinary tract infection in a given year, and half of women have at least one infection at some point in their lifetime.[4][7] They occur most frequently between the ages of 16 and 35 years.[7] Recurrences are common.[7] Urinary tract infections have been described since ancient times with the first documented description in the Ebers Papyrus dated to c. 1550 BC.[20]

Video summary (script)

Signs and symptoms

[edit]
Urine may contain pus (a condition known as pyuria) as seen from a person with sepsis due to a urinary tract infection.

Lower urinary tract infection is also referred to as a bladder infection. The most common symptoms are burning with urination and having to urinate frequently (or an urge to urinate) in the absence of vaginal discharge and significant pain.[4] These symptoms may vary from mild to severe[10] and in healthy women last an average of six days.[19] Some pain above the pubic bone or in the lower back may be present. People experiencing an upper urinary tract infection, or pyelonephritis, may experience flank pain, fever, or nausea and vomiting in addition to the classic symptoms of a lower urinary tract infection.[10] Rarely, the urine may appear bloody[7] or contain visible pus in the urine.[21]

UTIs have been associated with onset or worsening of delirium, dementia, and neuropsychiatric disorders such as depression and psychosis. However, there is insufficient evidence to determine whether UTI causes confusion.[22][23][24][25] The reasons for this are unknown, but may involve a UTI-mediated systemic inflammatory response which affects the brain.[22][23][26][27] Cytokines such as interleukin-6 produced as part of the inflammatory response may produce neuroinflammation, in turn affecting dopaminergic and/or glutamatergic neurotransmission as well as brain glucose metabolism.[22][23][26][27]

Children

[edit]

In young children, the only symptom of a urinary tract infection (UTI) may be a fever.[28] Because of the lack of more obvious symptoms, when females under the age of two or uncircumcised males less than a year exhibit a fever, a culture of the urine is recommended by many medical associations.[28] Infants may feed poorly, vomit, sleep more, or show signs of jaundice.[28] In older children, new onset urinary incontinence (loss of bladder control) may occur.[28] About 1 in 400 infants of one to three months of age with a UTI also have bacterial meningitis.[29]

Elderly

[edit]

Urinary tract symptoms are frequently lacking in the elderly.[11] The presentations may be vague and include incontinence, a change in mental status, or fatigue as the only symptoms,[10] while some present to a health care provider with sepsis, an infection of the blood, as the first symptoms.[7] Diagnosis can be complicated by the fact that many elderly people have preexisting incontinence or dementia.[11]

It is reasonable to obtain a urine culture in those with signs of systemic infection that may be unable to report urinary symptoms, such as when advanced dementia is present.[30] Systemic signs of infection include a fever or increase in temperature of more than 1.1 °C (2.0 °F) from usual, chills, and an increased white blood cell count.[30]

Cause

[edit]
Uropathogenic Escherichia coli (UPEC) cells adhered to bladder epithelial cell

Uropathogenic E. coli from the gut is the cause of 80–85% of community-acquired urinary tract infections,[31] with Staphylococcus saprophyticus being the cause in 5–10%.[4] Rarely they may be due to viral or fungal infections.[32] Healthcare-associated urinary tract infections (mostly related to urinary catheterization) involve a much broader range of pathogens including: E. coli (27%), Klebsiella (11%), Pseudomonas (11%), the fungal pathogen Candida albicans (9%), and Enterococcus (7%) among others.[7][33][34] During recent years of intensive care, Enterococcus spp. have several times been found as the primary cause of urinary tract infection, suggested related to broad treatment with cephalosporin antibiotics against which they are tolerant.[35][36][37] Urinary tract infections due to Staphylococcus aureus typically occur secondary to blood-borne infections.[10] Chlamydia trachomatis and Mycoplasma genitalium can infect the urethra but not the bladder.[38] These infections are usually classified as a urethritis rather than urinary tract infection.[39]

Intercourse

[edit]

In young sexually active women, sexual activity is the cause of 75–90% of bladder infections, with the risk of infection related to the frequency of sex.[4] The term "honeymoon cystitis" has been applied to this phenomenon of frequent UTIs during early marriage. In post-menopausal women, sexual activity does not affect the risk of developing a UTI.[4] Spermicide use, independent of sexual frequency, increases the risk of UTIs.[4] Diaphragm use is also associated.[40] Condom use without spermicide or use of birth control pills does not increase the risk of uncomplicated urinary tract infection.[4][41]

Sex

[edit]

Women are more prone to UTIs than men because, in females, the urethra is much shorter and closer to the anus.[42] As a woman's estrogen levels decrease with menopause, her risk of urinary tract infections increases due to the loss of protective vaginal flora.[42] Additionally, vaginal atrophy that can sometimes occur after menopause is associated with recurrent urinary tract infections.[43]

Chronic prostatitis in the forms of chronic prostatitis/chronic pelvic pain syndrome and chronic bacterial prostatitis (not acute bacterial prostatitis or asymptomatic inflammatory prostatitis) may cause recurrent urinary tract infections in males. Risk of infections increases as males age. While bacteria is commonly present in the urine of older males this does not appear to affect the risk of urinary tract infections.[44]

Urinary catheters

[edit]

Urinary catheterization increases the risk for urinary tract infections. The risk of bacteriuria (bacteria in the urine) is between three and six percent per day and prophylactic antibiotics are not effective in decreasing symptomatic infections.[42] The risk of an associated infection occurs linearly for enteric bacteria,[45][35] and can be decreased by catheterizing only when necessary, using aseptic technique for insertion, and maintaining unobstructed closed drainage of the catheter.[46][47][48]

Male scuba divers using condom catheters and female divers using external catching devices for their dry suits are also susceptible to urinary tract infections.[49]

Others

[edit]

A predisposition for bladder infections may run in families.[4] This is believed to be related to genetics.[4] Other risk factors include diabetes,[4] being uncircumcised,[50][51] and having a large prostate.[10] In children UTIs are associated with vesicoureteral reflux (an abnormal movement of urine from the bladder into ureters or kidneys) and constipation.[28]

Persons with spinal cord injury are at increased risk for urinary tract infection in part because of chronic use of catheter, and in part because of voiding dysfunction.[52] It is the most common cause of infection in this population, as well as the most common cause of hospitalization.[52]

Pathogenesis

[edit]
Bladder infection

The bacteria that cause urinary tract infections typically enter the bladder via the urethra. However, infection may also occur via the blood or lymph.[7] It is believed that the bacteria are usually transmitted to the urethra from the bowel, with females at greater risk due to their anatomy.[7] After gaining entry to the bladder, E. Coli are able to attach to the bladder wall and form a biofilm that resists the body's immune response.[7]

Escherichia coli is the single most common microorganism, followed by Klebsiella and Proteus spp., to cause urinary tract infection. Klebsiella and Proteus spp., are frequently associated with stone disease. The presence of Gram positive bacteria such as Enterococcus and Staphylococcus is increased.[53]

The increased resistance of urinary pathogens to quinolone antibiotics has been reported worldwide and might be the consequence of overuse and misuse of quinolones.[53]

Diagnosis

[edit]
Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) shown between white blood cells in urinary microscopy. These changes are indicative of a urinary tract infection.

In straightforward cases, a diagnosis may be made and treatment given based on symptoms alone without further laboratory confirmation.[4] In complicated or questionable cases, it may be useful to confirm the diagnosis via urinalysis, looking for the presence of urinary nitrites, white blood cells (leukocytes), or leukocyte esterase.[54] Another test, urine microscopy, looks for the presence of red blood cells, white blood cells, or bacteria. Urine culture is deemed positive if it shows a bacterial colony count of greater than or equal to 103 colony-forming units per mL of a typical urinary tract organism. Antibiotic sensitivity can also be tested with these cultures, making them useful in the selection of antibiotic treatment. However, women with negative cultures may still improve with antibiotic treatment.[4] As symptoms can be vague and without reliable tests for urinary tract infections, diagnosis can be difficult in the elderly.[11]

Based on pH

[edit]

Normal urine pH is slightly acidic, with usual values of 6.0 to 7.5, but the normal range is 4.5 to 8.0. A urine pH of 8.5 or 9.0 is indicative of a urea-splitting organism, such as Proteus, Klebsiella, or Ureaplasma urealyticum; therefore, an asymptomatic patient with a high pH means UTI regardless of the other urine test results. Alkaline pH also can signify struvite kidney stones, which are also known as "infection stones".[6]

Classification

[edit]

A urinary tract infection may involve only the lower urinary tract, in which case it is known as a bladder infection. Alternatively, it may involve the upper urinary tract, in which case it is known as pyelonephritis. If the urine contains significant bacteria but there are no symptoms, the condition is known as asymptomatic bacteriuria.[10] If a urinary tract infection involves the upper tract, and the person has diabetes mellitus, is pregnant, is male, or immunocompromised, it is considered complicated.[7][19] Otherwise if a woman is healthy and premenopausal it is considered uncomplicated.[19] In children when a urinary tract infection is associated with a fever, it is deemed to be an upper urinary tract infection.[28]

Children

[edit]

To make the diagnosis of a urinary tract infection in children, a positive urinary culture is required. Contamination poses a frequent challenge depending on the method of collection used, thus a cutoff of 105 CFU/mL is used for a "clean-catch" mid stream sample, 104 CFU/mL is used for catheter-obtained specimens, and 102 CFU/mL is used for suprapubic aspirations (a sample drawn directly from the bladder with a needle). The use of "urine bags" to collect samples is discouraged by the World Health Organization due to the high rate of contamination when cultured, and catheterization is preferred in those not toilet trained. Some, such as the American Academy of Pediatrics recommends renal ultrasound and voiding cystourethrogram (watching a person's urethra and urinary bladder with real time x-rays while they urinate) in all children less than two years old who have had a urinary tract infection. However, because there is a lack of effective treatment if problems are found, others such as the National Institute for Health and Care Excellence only recommends routine imaging in those less than six months old or who have unusual findings.[28]

Differential diagnosis

[edit]

In women with cervicitis (inflammation of the cervix) or vaginitis (inflammation of the vagina) and in young men with UTI symptoms, a Chlamydia trachomatis or Neisseria gonorrhoeae infection may be the cause.[10][55] These infections are typically classified as a urethritis rather than a urinary tract infection. Vaginitis may also be due to a yeast infection.[56] Interstitial cystitis (chronic pain in the bladder) may be considered for people who experience multiple episodes of UTI symptoms but urine cultures remain negative and not improved with antibiotics.[57] Prostatitis (inflammation of the prostate) may also be considered in the differential diagnosis.[58]

Hemorrhagic cystitis, characterized by blood in the urine, can occur secondary to a number of causes including: infections, radiation therapy, underlying cancer, medications and toxins.[59] Medications that commonly cause this problem include the chemotherapeutic agent cyclophosphamide with rates of 2–40%.[59] Eosinophilic cystitis is a rare condition where eosinophiles are present in the bladder wall.[60] Signs and symptoms are similar to a bladder infection.[60] Its cause is not entirely clear; however, it may be linked to food allergies, infections, and medications among others.[61]

Prevention

[edit]

A number of measures have not been confirmed to affect UTI frequency including: urinating immediately after intercourse, the type of underwear used, personal hygiene methods used after urinating or defecating, or whether a person typically bathes or showers.[4] There is similarly a lack of evidence surrounding the effect of holding one's urine, tampon use, and douching.[42] In those with frequent urinary tract infections who use spermicide or a diaphragm as a method of contraception, they are advised to use alternative methods.[7] In those with benign prostatic hyperplasia urinating in a sitting position appears to improve bladder emptying[62] which might decrease urinary tract infections in this group.[citation needed]

Using urinary catheters as little and as short of time as possible and appropriate care of the catheter when used prevents catheter-associated urinary tract infections.[46] They should be inserted using sterile technique in hospital however non-sterile technique may be appropriate in those who self catheterize.[48] The urinary catheter set up should also be kept sealed.[48] Evidence does not support a significant decrease in risk when silver-alloy catheters are used.[63]

Medications

[edit]
Trimethoprim-Sulfamethoxazole tablets, a commonly used antibiotic for UTI.

For those with recurrent infections, taking a short course of antibiotics when each infection occurs is associated with the lowest antibiotic use.[17] A prolonged course of daily antibiotics is also effective.[4] Medications frequently used include nitrofurantoin and trimethoprim/sulfamethoxazole.[7] Some recommend against prolonged use due to concerns of antibiotic resistance.[17] Methenamine is another agent used for this purpose as in the bladder where the acidity is low it produces formaldehyde to which resistance does not develop.[64] A UK study showed that methenamine is as effective daily low-dose antibiotics at preventing UTIs among women who experience recurrent UTIs. As methenamine is an antiseptic, it may avoid the issue of antibiotic resistance.[65][66]

In cases where infections are related to intercourse, taking antibiotics afterwards may be useful.[7] In post-menopausal women, topical vaginal estrogen has been found to reduce recurrence.[67][68] As opposed to topical creams, the use of vaginal estrogen from pessaries has not been as useful as low dose antibiotics.[68] Antibiotics following short term urinary catheterization decreases the subsequent risk of a bladder infection.[69] A number of UTI vaccines are in development as of 2018.[70][71]

Children

[edit]

The evidence that preventive antibiotics decrease urinary tract infections in children is poor.[72] However recurrent UTIs are a rare cause of further kidney problems if there are no underlying abnormalities of the kidneys, resulting in less than a third of a percent (0.33%) of chronic kidney disease in adults.[73]

Male circumcision

[edit]

Circumcision of boys has been observed to exhibit a strong protective effect against UTIs, with some research suggesting as much as a 90% reduction in symptomatic UTI incidence among male infants, if they are circumcised.[74][75] The protective effect is even stronger in boys born with urogenital abnormalities.[75]

Dietary supplements

[edit]

When used as an adjuvant to antibiotics and other standard treatments, cranberry supplements decrease the number of UTIs in people who get them frequently.[67][76][77] A 2023 review concluded that cranberry products can reduce the risk of UTIs in certain groups (women with reoccurring UTIs, children, and people having had clinical interventions), but not in pregnant women, the elderly or people with urination disorders.[78] Some evidence suggests that cranberry juice is more effective at UTI control than dehydrated tablets or capsules.[77] Cranberry has not been effective in attempts to replace antibiotics for the treatment of active infections.[79] Cranberry supplements are also high in sugar content, which may worsen the risks associated with UTIs in patients with diabetes mellitus.[80]

D-mannose is often marketed as a dietary supplement that prevents UTIs; however, there is little evidence supporting its use. A randomised controlled trial compared daily d-mannose with a placebo (fructose) among women with recurrent urinary tract infections over 6 months. D-mannose offered no benefit over placebo in reducing UTIs.[81][82]

As of 2015, probiotics require further study to determine if they are beneficial for UTI.[83]

Treatment

[edit]

The mainstay of treatment is antibiotics. Phenazopyridine is occasionally prescribed during the first few days in addition to antibiotics to help with the burning and urgency sometimes felt during a bladder infection.[84] However, it is not routinely recommended due to safety concerns with its use, specifically an elevated risk of methemoglobinemia (higher than normal level of methemoglobin in the blood).[85] Paracetamol may be used for fevers.[86] There is no good evidence for the use of cranberry products for treating current infections.[87][88]

Fosfomycin can be used as an effective treatment for both UTIs and complicated UTIs including acute pyelonephritis.[89] The standard regimen for complicated UTIs is an oral 3g dose administered once every 48 or 72 hours for a total of 3 doses or a 6 grams every 8 hours for 7 days to 14 days when fosfomycin is given in IV form.[89]

Gepotidacin was approved for medical use in the United States in March 2025.[90] It is the first new antibiotic approved in the US for UTIs in nearly 30 years.[91][92]

Uncomplicated

[edit]

Uncomplicated infections can be diagnosed and treated based on symptoms alone.[4] Antibiotics taken by mouth such as trimethoprim/sulfamethoxazole, nitrofurantoin, or fosfomycin are typically first line.[93] Cephalosporins, amoxicillin/clavulanic acid, or a fluoroquinolone may also be used.[94] However, antibiotic resistance to fluoroquinolones among the bacteria that cause urinary infections has been increasing.[54] The Food and Drug Administration (FDA) recommends against the use of fluoroquinolones, including a Boxed Warning, when other options are available due to higher risks of serious side effects, such as tendinitis, tendon rupture and worsening of myasthenia gravis.[95] These medications substantially shorten the time to recovery with all being equally effective.[94][96] A three-day treatment with trimethoprim/sulfamethoxazole, or a fluoroquinolone is usually sufficient, whereas nitrofurantoin requires 5–7 days.[4][97] Fosfomycin may be used as a single dose but is not as effective.[54]

Fluoroquinolones are not recommended as a first treatment.[54][98] The Infectious Diseases Society of America states this due to the concern of generating resistance to this class of medication.[97] Amoxicillin-clavulanate appears less effective than other options.[99] Despite this precaution, some resistance has developed to all of these medications related to their widespread use.[4] Trimethoprim alone is deemed to be equivalent to trimethoprim/sulfamethoxazole in some countries.[97] For simple UTIs, children often respond to a three-day course of antibiotics.[100] Women with recurrent simple UTIs are over 90% accurate in identifying new infections.[4] They may benefit from self-treatment upon occurrence of symptoms with medical follow-up only if the initial treatment fails.[4]

The combination sulopenem etzadroxil/probenecid (Orlynvah) was approved for medical use in the United States in October 2024.[101][102]

Complicated

[edit]

Complicated UTIs are more difficult to treat and usually requires more aggressive evaluation, treatment, and follow-up.[103] It may require identifying and addressing the underlying complication.[104] Increasing antibiotic resistance is causing concern about the future of treating those with complicated and recurrent UTI.[105][106][107]

Asymptomatic bacteriuria

[edit]

Those who have bacteria in the urine but no symptoms should not generally be treated with antibiotics.[108] This includes those who are old, those with spinal cord injuries, and those who have urinary catheters.[109][110] Pregnancy is an exception and it is recommended that women take seven days of antibiotics.[111][112] If not treated it causes up to 30% of mothers to develop pyelonephritis and increases risk of low birth weight and preterm birth.[113] Some also support treatment of those with diabetes mellitus[114] and treatment before urinary tract procedures which will likely cause bleeding.[110]

Pregnant women

[edit]

Urinary tract infections, even asymptomatic presence of bacteria in the urine, are more concerning in pregnancy due to the increased risk of kidney infections.[42] During pregnancy, high progesterone levels elevate the risk of decreased muscle tone of the ureters and bladder, which leads to a greater likelihood of reflux, where urine flows back up the ureters and towards the kidneys.[42] While pregnant women do not have an increased risk of asymptomatic bacteriuria, if bacteriuria is present they do have a 25–40% risk of a kidney infection.[42] Thus if urine testing shows signs of an infection—even in the absence of symptoms—treatment is recommended.[113][112] Cephalexin or nitrofurantoin are typically used because they are generally considered safe in pregnancy.[112] A kidney infection during pregnancy may result in preterm birth or pre-eclampsia (a state of high blood pressure and kidney dysfunction during pregnancy that can lead to seizures).[42] Some women have UTIs that keep coming back in pregnancy.[115] There is insufficient research on how to best treat these recurrent infections.[115]

Pyelonephritis

[edit]

Pyelonephritis is treated more aggressively than a simple bladder infection using either a longer course of oral antibiotics or intravenous antibiotics.[3] Seven days of the oral fluoroquinolone ciprofloxacin is typically used in areas where the resistance rate is less than 10%. If the local antibiotic resistance rates are greater than 10%, a dose of intravenous ceftriaxone is often prescribed.[3] Trimethoprim/sulfamethoxazole or amoxicillin/clavulanate orally for 14 days is another reasonable option.[116] In those who exhibit more severe symptoms, admission to a hospital for ongoing antibiotics may be needed.[3] Complications such as ureteral obstruction from a kidney stone may be considered if symptoms do not improve following two or three days of treatment.[10][3]

Prognosis

[edit]

With treatment, symptoms generally improve within 36 hours.[19] Up to 42% of uncomplicated infections may resolve on their own within a few days or weeks.[4][117]

15–25% of adults and children have chronic symptomatic UTIs including recurrent infections, persistent infections (infection with the same pathogen), a re-infection (new pathogen), or a relapsed infection (the same pathogen causes a new infection after it was completely gone).[118] Recurrent urinary tract infections are defined as at least two infections (episodes) in a six-month time period or three infections in twelve months, can occur in adults and in children.[118]

Cystitis refers to a urinary tract infection that involves the lower urinary tract (bladder). An upper urinary tract infection which involves the kidney is called pyelonephritis. About 10–20% of pyelonephritis will go on and develop scarring of the affected kidney. Then, 10–20% of those develop scarring will have increased risk of hypertension in later life.[119]

Epidemiology

[edit]

Urinary tract infections are the most frequent bacterial infection in women.[19] They occur most frequently between the ages of 16 and 35 years, with 10% of women getting an infection yearly and more than 40–60% having an infection at some point in their lives.[7][4] Recurrences are common, with nearly half of people getting a second infection within a year. Urinary tract infections occur four times more frequently in females than males.[7] Pyelonephritis occurs between 20 and 30 times less frequently.[4] They are the most common cause of hospital-acquired infections accounting for approximately 40%.[120] Rates of asymptomatic bacteria in the urine increase with age from two to seven percent in women of child-bearing age to as high as 50% in elderly women in care homes.[42] Rates of asymptomatic bacteria in the urine among men over 75 are between 7–10%.[11] 2–10% of pregnant women have asymptomatic bacteria in the urine and higher rates are reported in women who live in some underdeveloped countries.[113]

Urinary tract infections may affect 10% of people during childhood.[7] Among children, urinary tract infections are most common in uncircumcised males less than three months of age, followed by females less than one year.[28] Estimates of frequency among children, however, vary widely. In a group of children with a fever, ranging in age between birth and two years, 2–20% were diagnosed with a UTI.[28]

Veterinary medicine

[edit]

Domestic cats are less susceptible to bacterial urinary tract infections than domestic dogs.[121]

History

[edit]

Urinary tract infections have been described since ancient times with the first documented description in the Ebers Papyrus dated to c. 1550 BC.[20] It was described by the Egyptians as "sending forth heat from the bladder".[122] Effective treatment did not occur until the development and availability of antibiotics in the 1930s, before which time herbs, bloodletting and rest were recommended.[20]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Urinary tract infection

View on Grokipedia
from Grokipedia
A urinary tract infection (UTI) is a common bacterial infection that affects part of the , which includes the kidneys, ureters, , and , and is most often caused by bacteria such as entering through the from the skin or . UTIs are among the most prevalent bacterial infections globally, occurring in both community and healthcare settings, with a lifetime risk of 50–60% for adult women due to anatomical factors like a shorter . They are the most common type of healthcare-associated infection, accounting for more than 30% of infections reported by hospitals. The majority of UTIs are uncomplicated and affect the lower urinary tract, manifesting as cystitis (bladder infection), while untreated cases can ascend to the kidneys, causing more severe pyelonephritis. Common symptoms, which are generally similar in both men and women, include a strong, persistent urge to urinate with frequent small volumes, a burning sensation during urination (dysuria), cloudy, bloody, or strong-smelling urine, and lower abdominal or pelvic pain; kidney involvement may add fever, chills, nausea, vomiting, and flank pain. Women are disproportionately affected, with nearly one in three experiencing at least one episode requiring antimicrobial therapy by age 24, though men, young children, older adults, and those with catheters or underlying conditions like diabetes also face elevated risks. Diagnosis typically involves a , , to detect or , and urine culture to identify the and guide . Treatment relies on antibiotics, such as , trimethoprim-sulfamethoxazole, or fosfomycin for uncomplicated cases, usually for 1–3 days in healthy non-pregnant women, though longer courses or intravenous administration may be needed for complicated or severe infections. Recurrent UTIs, defined as two or more in six months or three or more in a year, may require preventive strategies like low-dose prophylactic antibiotics or post-intercourse dosing. Prevention focuses on hygiene and lifestyle measures, including drinking adequate fluids (at least 1.5 liters of daily), urinating after sexual activity, wiping from front to back, and avoiding irritants like spermicides or diaphragms; for postmenopausal women, topical may reduce risk by restoring . Prompt medical attention is essential for symptoms suggesting upper tract involvement or in vulnerable populations to prevent complications like or chronic kidney damage.

Definition and Classification

Definition

A urinary tract infection (UTI) is an infection in any part of the , which consists of the kidneys, ureters (tubes connecting the kidneys to the ), , and (the tube through which exits the body). Most UTIs involve the lower urinary tract, particularly the (known as cystitis) or (), while infections in the upper tract affect the kidneys () or ureters and are typically more severe. infections represent the most common form of UTI, occurring when enter and multiply in the . UTIs are primarily bacterial in origin, with bacteria—most often from the —entering the and ascending into the urinary tract. Other pathogens, such as , , , and , can also cause , though less frequently. In some cases, sexually transmitted infections like or may contribute to urethral infections. An uncomplicated UTI refers to a bacterial infection of the and associated structures in otherwise healthy individuals without underlying urinary tract abnormalities or significant comorbidities. UTIs are among the most common bacterial infections worldwide, affecting approximately 50% of women at least once in their lifetime, with about 25% experiencing recurrent episodes. They are far less common in men under 50 years old but increase with age due to factors like enlargement. If untreated, lower tract infections can ascend to the kidneys, potentially leading to serious complications such as permanent kidney damage.

Types and Classification

Urinary tract infections (UTIs) are primarily classified based on anatomical location and clinical context, distinguishing between lower and upper tract involvement. Lower UTIs affect the bladder and urethra, manifesting as cystitis or urethritis, while upper UTIs involve the kidneys and ureters, typically as pyelonephritis. Lower urinary tract infections include cystitis, an inflammation of the bladder characterized by symptoms such as dysuria, urinary frequency, urgency, and suprapubic pain, often without systemic signs like fever. Urethritis, inflammation of the urethra, may present with similar local symptoms but can also involve discharge or discomfort during urination. In males, lower UTIs can extend to prostatitis (prostate gland infection) or epididymitis (epididymis inflammation), though these are less common and often classified separately due to their anatomical specificity. These infections are generally confined to the lower tract and respond well to short-course antibiotics in healthy hosts. Upper urinary tract infections, such as , involve the kidneys and are marked by more severe symptoms including high fever, flank pain, , , and chills, potentially leading to bacteremia if untreated. This is critical as upper UTIs carry a higher risk of complications like or renal scarring. Clinical of UTIs has traditionally divided them into uncomplicated and complicated, based on host factors and infection severity, with uncomplicated cases occurring in healthy premenopausal, non-pregnant women without urinary tract abnormalities, and complicated cases involving predisposing factors like catheters, , or . However, as of 2025, major guidelines have updated this framework to better reflect clinical presentation and patient-specific risks. The 2025 Infectious Diseases Society of America (IDSA) guidelines classify UTIs based on symptoms and point-of-care factors: uncomplicated UTIs are confined to the in afebrile individuals, while complicated UTIs (cUTIs) include those with systemic signs (e.g., fever), upper tract involvement, or risk factors like catheterization, applicable to both sexes. This revision emphasizes and immediate clinical assessment over detailed urologic evaluation, guiding treatment rather than . Similarly, the 2025 European Association of Urology (EAU) guidelines introduce a risk-stratified system: localized UTIs (e.g., cystitis without systemic signs) versus systemic UTIs (e.g., with fever), further categorized by risk level—low (healthy individuals), moderate (mild comorbidities), high (severe factors like or anatomical issues)—and healthcare-associated UTIs (e.g., catheter-related). Male sex is no longer considered an inherent complicating factor; classification focuses on individual risks, local resistance, and infection severity to tailor diagnostics (e.g., , ) and antimicrobials, promoting . Catheter-associated UTIs, often high-risk or healthcare-associated, account for up to 80% of hospital-acquired UTIs and are linked to formation on devices. Additional categorizations include recurrent UTIs, defined as three or more episodes within 12 months or two within six months, often due to reinfection by the same and requiring prophylaxis in select cases. UTIs are also distinguished as acute (sudden onset, self-limited in low-risk cases) versus chronic (persistent or recurrent with underlying issues), though represents a specific chronic form primarily in men. These classifications guide , treatment duration, and empirical choices, emphasizing confirmation in higher-risk cases.

Causes and Risk Factors

Pathogens

Urinary tract infections (UTIs) are predominantly caused by bacterial pathogens, which account for the vast majority of cases worldwide. Among these, uropathogenic Escherichia coli (UPEC) is the leading cause, responsible for approximately 80-90% of community-acquired UTIs and 30-50% of hospital-acquired infections. Other Gram-negative bacteria, such as Klebsiella pneumoniae and Proteus mirabilis, are also frequent contributors, particularly in complicated or catheter-associated cases, with P. mirabilis implicated in 1-10% of UTIs due to its urease production that promotes stone formation and persistent infection. Gram-positive bacteria play a secondary role but are significant in specific contexts; Enterococcus faecalis is common in ascending infections and accounts for a notable portion of hospital-acquired UTIs, while Staphylococcus saprophyticus is a key in young, sexually active women, causing 5-15% of uncomplicated cystitis cases. emerges as the third most common in nosocomial settings, responsible for about 9% of hospital-acquired UTIs, often in patients with indwelling catheters or . These bacteria typically originate from the , skin, or perineal area and ascend the to infect the or upper urinary tract. Fungal pathogens are far less common, primarily affecting immunocompromised individuals, those with prolonged catheterization, or patients on broad-spectrum antibiotics; is the most frequent fungal culprit, causing up to 10-20% of UTIs in high-risk hospital populations but rarely in otherwise healthy individuals. Other Candida species, such as C. glabrata and C. tropicalis, may also be involved, often leading to candiduria that can progress to disseminated infection if untreated. Viral and parasitic causes of UTIs are exceedingly rare and typically occur in immunocompromised hosts, such as transplant recipients or those with . Viruses like (CMV), BK polyomavirus (type 1 human polyomavirus), (HSV), and adenovirus have been documented in isolated cases, often via hematogenous spread rather than ascending infection. Parasites, such as , are geographically limited, primarily causing UTIs in endemic areas like through chronic bladder inflammation. Additionally, sexually transmitted infections including , , and can cause , a subtype of lower UTI, particularly in adolescents and young adults.
Pathogen CategoryCommon ExamplesTypical Prevalence/Context
Bacterial (Gram-negative), , , 70-90% overall; dominant in community and hospital settings
Bacterial (Gram-positive), , 10-20%; common in catheterized or recurrent cases
Fungal, Candida glabrata<5%; high-risk patients (e.g., diabetics, catheterized)
Viral/OtherCMV, BK virus, HSV, Chlamydia trachomatis<1%; immunocompromised or STI-related

Risk Factors

Urinary tract infections (UTIs) are influenced by a range of risk factors that can be anatomical, behavioral, medical, or genetic in nature, with women facing a significantly higher lifetime risk—approximately 50%—compared to men due to the shorter female urethra, which facilitates bacterial ascent from the perineal area. Anatomical abnormalities, such as vesicoureteral reflux present at birth, allow urine to flow backward from the bladder to the kidneys, promoting bacterial proliferation and recurrent infections. Obstructions such as kidney stones or, particularly in older men, benign prostatic hyperplasia (BPH)—which affects approximately 80% of men over 70 years of age and commonly causes urinary retention—can impede urine flow, leading to stasis and bacterial growth. Urinary incontinence or prolapse, such as cystocele, contributes to incomplete bladder emptying, a key predisposing factor especially in older adults. Behavioral factors play a prominent role, particularly in premenopausal women; frequent penetrative sexual intercourse (more than four times per week) mechanically introduces bacteria from the gastrointestinal tract into the urethra through friction and close contact in the perineal area, while delayed urination after intercourse exacerbates this risk. The risk associated with sexual activity stems from this mechanical introduction of intestinal bacteria (such as E. coli) rather than from isolated female sexual arousal, natural vaginal lubrication, or the spreading of vaginal fluids on the vulva, as vaginal secretions do not typically contain or transmit uropathogenic bacteria. Use of spermicides or diaphragms as birth control alters vaginal flora, increasing susceptibility. Poor personal hygiene, particularly wiping from back to front after defecation in females, can transfer fecal bacteria from the anus directly to the urethral opening. In contrast, actions such as touching the anus and then the nose do not provide a pathway for bacteria to reach the urethra and do not cause UTIs or associated symptoms such as dysuria, fever, headache, or dark urine. These symptoms result from direct contamination of the urethral area with fecal bacteria (e.g., E. coli), typically through improper perineal hygiene, sexual activity, or direct contact of contaminated fingers with the genitals. Low fluid intake reduces urinary flushing of bacteria, and constipation may indirectly promote infection by affecting pelvic pressure and hygiene. Medical conditions heighten vulnerability across populations; diabetes impairs immune response and glycosuria fosters bacterial growth, while immunosuppression from conditions like HIV or treatments such as chemotherapy diminishes host defenses against uropathogens. Pregnancy alters urinary tract dynamics due to hormonal changes and uterine pressure on the bladder, elevating risk, and postmenopausal estrogen decline causes urogenital tissue atrophy, reduced epithelial thickness in the vagina, urethra, and bladder, a shift to higher vaginal pH, and diminished lactobacilli dominance, which produce acid to inhibit pathogens, thereby facilitating pathogenic bacterial overgrowth and ascension to the urinary tract. Indwelling catheters, used in hospitalized or mobility-impaired patients, introduce bacteria directly and promote biofilm formation, accounting for 70-80% of hospital-acquired UTIs in the United States. Recent urinary tract procedures, such as cystoscopy, also transiently increase infection likelihood by breaching natural barriers. Genetic predispositions, including family history of UTIs and non-secretor blood group status, are associated with heightened susceptibility, likely due to variations in innate immune responses and epithelial receptor expression that facilitate bacterial adhesion. Obesity further compounds risk by promoting insulin resistance and altering microbiota, while neurogenic bladder from conditions like spinal cord injury leads to retention and incomplete voiding. A prior UTI history independently elevates recurrence risk by 20-30% in affected individuals.

Pathogenesis

Mechanisms of Infection

Urinary tract infections (UTIs) primarily arise from the ascension of uropathogenic bacteria from the external genitalia through the urethra into the bladder, with the majority of cases caused by uropathogenic Escherichia coli (UPEC). This process begins with colonization of the periurethral and urethral mucosa, primarily originating from the gastrointestinal tract via direct migration across the perineal area to the urethral opening, where bacteria exploit disruptions in local microbiota or mechanical barriers such as poor hygiene, sexual activity, or direct fecal contamination of the genital area. Bacterial ascension to cause UTI requires direct access to the periurethral and urethral mucosa from the perineal area; indirect transfer (e.g., touching the anus and then the nose) may contaminate nasal passages but does not lead to urethral colonization or systemic/urinary symptoms like fever, headache, dark urine, or dysuria. The normal vaginal flora, dominated by lactobacilli, is generally protective against uropathogens and is not a significant source of bacteria such as E. coli. Sexual activity facilitates bacterial ascent primarily through mechanical means rather than via vaginal secretions themselves. Motility via flagella enables initial upward migration against urine flow, a critical step in overcoming the urinary tract's natural flushing mechanism during micturition. Upon reaching the bladder, bacterial adhesion to the uroepithelium is mediated by specialized virulence factors, particularly type 1 pili on UPEC, which feature the adhesin FimH that binds mannose residues on uroplakins and integrins of superficial umbrella cells. This attachment prevents mechanical clearance by voiding and initiates colonization, allowing bacteria to form dense intracellular bacterial communities (IBCs) within host cells through actin-dependent endocytosis. Within IBCs, UPEC rapidly proliferates, differentiating into quiescent forms that evade immune detection and antibiotics, contributing to persistent or recurrent infections. Additional virulence factors, such as α-hemolysin (HlyA), disrupt host cell membranes to release nutrients and promote tissue damage, while siderophores like yersiniabactin facilitate iron acquisition in the nutrient-limited urinary environment. For ascending infections leading to pyelonephritis, bacteria traverse the ureters to the kidneys, often via P pili (PapG adhesin) that bind glycolipids on renal pelvic epithelium, exacerbating systemic inflammation. Other pathogens, such as Proteus mirabilis, employ distinct mechanisms including urease production, which hydrolyzes urea to ammonia, alkalinizing urine and promoting struvite stone formation that shields biofilms from host defenses. Immune evasion strategies across uropathogens include filamentation to resist phagocytosis and modulation of Toll-like receptor (TLR) signaling, such as UPEC's TcpC protein inhibiting TLR4-mediated cytokine release, thereby dampening neutrophil recruitment and epithelial exfoliation. These coordinated mechanisms underscore the pathogen's ability to subvert host barriers, leading to symptomatic infection when bacterial burden overwhelms innate defenses; bacterial invasion of the bladder mucosa triggers cystitis, an inflammatory response that irritates the bladder and urethral lining, heightening afferent nerve sensitivity and causing frequent urination urges with small volumes despite low fluid intake, accompanied by dysuria (burning pain), urgency, cloudy urine, and possible fever.

Host Response and Factors

The host immune response to urinary tract infection (UTI) primarily involves innate mechanisms that provide rapid defense against invading uropathogens, particularly uropathogenic Escherichia coli (UPEC), which accounts for approximately 80% of cases. Urothelial epithelial cells serve as the first line of defense, recognizing bacterial components such as lipopolysaccharide via (TLR4), which activates signaling pathways leading to the production of proinflammatory cytokines like IL-6 and IL-8. These cytokines recruit neutrophils to the site of infection within hours, where they phagocytose and kill bacteria through oxidative bursts and release of antimicrobial peptides, including cathelicidin (LL-37) and β-defensins, contributing to bacterial clearance. Additionally, epithelial cells promote pathogen expulsion through exocytosis of RAB27b+ vesicles and urothelial cell shedding, which removes adherent bacteria but can cause tissue damage if excessive. Mast cells and macrophages also play crucial roles in modulating the innate response. Mast cells release histamine and IL-10 to initiate inflammation and facilitate resolution, while resident bladder macrophages harbor approximately 60–80% of the bacteria found within the MHC II+ antigen-presenting cell compartment, preventing widespread dissemination but potentially sequestering bacteria in quiescent intracellular reservoirs that evade clearance. This sequestration can limit antigen presentation to dendritic cells, thereby dampening subsequent immune activation. Antimicrobial proteins such as lipocalin-2 (NGAL) and pentraxin 3 (PTX3) further enhance innate defense by binding iron-siderophore complexes and opsonizing bacteria for phagocytosis, respectively. Adaptive immunity develops following initial innate responses but often fails to confer sterilizing immunity against recurrent UTIs. T cells, particularly CD4+ and CD8+ subsets, infiltrate the bladder mucosa during secondary infections, improving bacterial clearance through cytokine production and cytotoxic activity; depletion of T cells abolishes this enhanced response in experimental models. B cells contribute by producing secretory IgA and IgG antibodies that inhibit bacterial adhesion to uroplakins on epithelial surfaces, with prior exposure leading to elevated urinary IgA levels that correlate with reduced recurrence in some hosts. However, macrophages can subvert adaptive responses by limiting dendritic cell access to antigens, resulting in suboptimal T and B cell priming and persistent susceptibility to reinfection. Host factors significantly influence the efficacy of these immune responses during UTI pathogenesis. Genetic polymorphisms in innate immune genes, such as TLR4 Asp299Gly and TLR5 R392X, impair pathogen recognition and increase infection susceptibility by reducing cytokine production and neutrophil recruitment. Vitamin D deficiency, with prevalence up to 62.5% in premenopausal women with recurrent UTIs as reported in one study, diminishes cathelicidin expression and antimicrobial activity, exacerbating bacterial persistence. Physiological factors like estrogen decline in postmenopausal women delay neutrophil influx and prolong inflammation via upregulated COX-2 expression, leading to chronic cystitis. Aging further compromises responses through reduced urothelial proliferation and impaired IL-17-mediated neutrophil activation, heightening recurrence risk. Prior infections can imprint the bladder mucosa, sensitizing it to exaggerated IL-6/STAT3 signaling that promotes bacterial reservoirs despite robust initial clearance.

Clinical Presentation

Signs and Symptoms in Adults

Urinary tract infections (UTIs) in adults commonly present with symptoms related to the lower urinary tract, such as the bladder and urethra, or the upper tract involving the kidneys. Symptoms are generally similar in men and women, though UTIs are more common in women due to their shorter urethra. Common symptoms in both include burning or pain during urination (dysuria), frequent urge to urinate often with small amounts, strong persistent need to urinate (urgency), cloudy, bloody, or strong-smelling urine, and lower abdominal or pelvic pain. In men, UTIs are less common and may involve the prostate (prostatitis), potentially causing rectal pain or other complications, but core urinary symptoms remain the same. The most frequent manifestations include dysuria, a painful or burning sensation during urination, which affects a significant portion of patients. Urinary frequency, characterized by the need to urinate more often than usual, and urgency, an abrupt and strong compulsion to void, are also hallmark symptoms that disrupt daily activities. Additionally, patients often experience suprapubic discomfort or pressure in the lower abdomen, sometimes accompanied by cramping or a sensation of incomplete bladder emptying. Although dysuria is a hallmark symptom of UTIs, urinary tract infections do not typically cause inflammation of the vulva or inflamed bumps in the genital area. Such findings are more commonly associated with vulvovaginitis, candidiasis (yeast infections), bacterial vaginosis, herpes simplex virus infections, Bartholin cysts, or other genital conditions. While both UTIs and certain vaginal infections can cause dysuria, the presence of vulvar inflammation, vaginal discharge, or external genital lesions typically indicates a gynecologic condition rather than a UTI alone. Dysuria associated with UTIs is characteristically internal (felt in the bladder or urethra), whereas external dysuria accompanied by vulvar irritation or discharge is more suggestive of vulvovaginitis or similar disorders. In cases of lower UTI, such as cystitis, hematuria (visible or microscopic blood in the urine) may occur, leading to cloudy, reddish, or foul-smelling urine. Hesitancy, or difficulty initiating the urine stream, and bladder spasms can further contribute to discomfort. These symptoms typically arise without systemic involvement, distinguishing uncomplicated lower UTIs from more severe forms. Upper UTIs, like pyelonephritis, involve additional systemic and localized signs indicating kidney involvement (in both genders), such as back or side pain, fever, chills, nausea, and vomiting. Fever, often exceeding 38°C, chills, and flank pain (tenderness in the lower back or side) are prominent, along with nausea and vomiting. Lower back pain below the ribs may radiate and intensify with movement. Physical examination might reveal costovertebral angle tenderness in affected individuals. Symptoms of UTIs can overlap with those of kidney stones, particularly painful urination (dysuria), frequent urge to urinate, and blood in the urine (hematuria). However, key differences help distinguish them. Kidney stones typically cause severe, sharp, colicky pain in the back, side, or abdomen that occurs in waves and radiates to the groin, often accompanied by nausea and vomiting. In contrast, UTI-related pain is more commonly a burning sensation during urination and discomfort or pressure in the lower abdomen or pelvis. UTIs prominently feature cloudy or foul-smelling urine and frequent small-volume urination, while kidney stones more commonly cause visible (gross) hematuria (pink, red, or brown urine). Fever and chills are characteristic of ascending UTIs (pyelonephritis), though they may also occur with kidney stones if complicated by infection. Kidney stones can lead to secondary UTIs due to obstruction and urinary stasis. Accurate diagnosis requires medical evaluation, often involving urinalysis, culture, and imaging. Certain adult populations, particularly older adults, may exhibit atypical presentations. In elderly patients, symptoms can include confusion, lethargy, or generalized malaise rather than classic urinary complaints, with nocturia or incontinence as subtle indicators. Fatigue, shakiness, or changes in mental status underscore the need for heightened clinical suspicion in this group. Overall, prompt recognition of these varied signs is essential, as untreated UTIs can progress to complications.

Signs and Symptoms in Special Populations

In children, particularly infants and those under 2 years of age, urinary tract infections (UTIs) often present with nonspecific symptoms that can mimic other childhood illnesses, making diagnosis challenging without laboratory confirmation. Common signs include fever, irritability or fussiness, poor feeding or appetite leading to poor weight gain, and vomiting or diarrhea. In older children aged 2 years and above, symptoms more closely resemble those in adults, such as pain or burning during urination, frequent or urgent need to urinate, bloody or foul-smelling urine, abdominal pain, and bedwetting in previously toilet-trained children; fever may also occur, especially with kidney involvement. For pyelonephritis in children of any age, additional features like chills, nausea, vomiting, and pain in the back, side, or groin are typical. In older adults, UTIs frequently manifest atypically due to age-related changes in immune response and comorbidities, often lacking classic urinary symptoms and instead presenting with systemic or behavioral alterations. These may include sudden confusion, delirium, lethargy, disorganized speech, drowsiness, frequent falls, worsening mental status, urinary incontinence, poor appetite, hypotension, tachycardia, or general unwellness; nocturia and urgency have limited diagnostic value in this group. When urinary symptoms do appear, they can involve new or increased burning on urination, frequency, urgency, flank or suprapubic pain, fever or chills, and changes in urine character, appearance, or control. Such nonspecific presentations contribute to frequent misdiagnosis, with asymptomatic bacteriuria often confused for infection, affecting up to 40-50% of care home residents. Pregnant women experience UTIs with symptoms largely similar to non-pregnant adults, but physiological changes like urinary stasis increase the prevalence of asymptomatic bacteriuria (2-13%) and the risk of progression to symptomatic infection. For cystitis, hallmark signs include dysuria (in about 55% of cases), urinary frequency (82%), urgency, and suprapubic pain or tenderness (73%); lower abdominal or back pain, along with cloudy, dark, bloody, or foul-smelling urine, may also occur. Pyelonephritis, a more serious complication, typically features fever (≥38.0°C), chills, flank pain, malaise, anorexia, nausea, vomiting, tachycardia, hypotension, and uterine contractions due to smooth muscle irritability; prompt recognition is critical to prevent maternal sepsis or adverse fetal outcomes like preterm delivery. In immunocompromised patients, such as those with diabetes, HIV, post-chemotherapy states, organ transplants, or on corticosteroids, UTIs often present with atypical, nonspecific, or absent local symptoms, heightening the risk of rapid progression to severe complications like sepsis or septic shock. Manifestations may include delirium (especially in older individuals), signs mimicking an acute abdomen, fever, chills, flank pain, fatigue, mental status changes, or graft dysfunction in transplant recipients; dysuria, urgency, frequency, suprapubic pain, and hematuria can occur but are less reliable indicators. In spinal cord-injured or catheterized immunocompromised individuals, additional signs like autonomic dysreflexia (hypertension, headache), increased spasticity, cloudy or foul-smelling urine, or low-grade fever may signal infection, often requiring systemic symptoms for treatment decisions. Viral etiologies, such as hemorrhagic cystitis, are more common in this population and can exacerbate symptom severity.

Diagnosis

Clinical Assessment

Clinical assessment of urinary tract infections (UTIs) begins with a detailed patient history to identify characteristic symptoms and risk factors, enabling initial differentiation between uncomplicated and complicated cases. Typical symptoms of lower UTI, such as cystitis, include dysuria, urinary frequency, urgency, suprapubic pain, and sometimes gross hematuria, which are often acute in onset and more common in premenopausal women. In contrast, upper UTI like pyelonephritis presents with systemic signs including fever, chills, nausea, vomiting, and flank pain, alongside lower tract symptoms. Elderly patients or those with comorbidities may exhibit atypical or nonspecific symptoms, such as confusion, falls, or acute mental status changes, rather than classic urinary complaints. During history taking, clinicians evaluate predisposing factors to classify the infection's complexity and guide further evaluation. Risk factors for complicated UTI include male sex, indwelling catheters, urinary tract obstructions (e.g., stones or strictures), immunosuppression, pregnancy, diabetes, or recent urinary tract instrumentation, which increase the likelihood of resistant pathogens or treatment failure. Prior antibiotic exposure, recurrent UTIs, and recent urine culture results should also be reviewed to inform empiric therapy choices and avoid agents like fluoroquinolones if used within the past 12 months. In catheterized patients, symptoms may manifest as fever, rigors, flank pain, acute hematuria, or purulent discharge from the catheter site. Differentiation from other conditions, such as vaginitis (suggested by vaginal discharge, odor, or dyspareunia) or sexually transmitted infections, is essential, particularly in women with dysuria; vulvar inflammation, swelling, or inflamed bumps are not typical of UTI and more commonly indicate alternative diagnoses such as vulvovaginitis, candidiasis, bacterial vaginosis, herpes, or Bartholin cysts. Nephrolithiasis (kidney stones) is another important differential diagnosis, especially in patients presenting with hematuria, flank pain, or abdominal pain. UTIs and kidney stones share some symptoms, including painful urination, urinary frequency or urgency, and hematuria. However, key differences include pain characteristics: kidney stones typically cause severe, sharp, cramping (colicky) pain in the back, side, abdomen, or groin that comes in waves and may radiate, whereas UTIs often cause a burning sensation during urination and discomfort or pressure in the lower abdomen or pelvis. Urinary symptoms in UTIs prominently feature burning with urination, cloudy or foul-smelling urine, and frequent small-volume urination, while kidney stones more commonly cause visible gross hematuria (pink, red, or brown urine) and may lead to nausea or vomiting. Kidney stones are more likely to cause intense pain, nausea, and vomiting; UTIs may involve fever and chills if the infection ascends to the kidneys. Overlaps occur, particularly if a kidney stone causes obstruction leading to secondary infection. Accurate diagnosis requires medical evaluation, including history, physical examination, laboratory tests, and potentially imaging. Physical examination complements the history by assessing for localized tenderness and systemic illness severity. Suprapubic tenderness may be elicited in cystitis, occurring in 10-20% of uncomplicated cases, while costovertebral angle tenderness indicates possible pyelonephritis. Vital signs evaluation is critical; fever greater than 38°C or hemodynamic instability suggests upper tract involvement or sepsis, warranting urgent assessment using tools like qSOFA or SIRS criteria. A pelvic examination is recommended for recurrent UTIs or suspected pelvic organ prolapse. In complicated cases, examination may reveal signs of underlying structural issues, such as an enlarged bladder or abdominal masses, though the exam is often unremarkable in uncomplicated lower UTIs. Overall, clinical assessment relies on integrating symptoms, risk factors, and exam findings to establish diagnostic probability before laboratory confirmation. A high pretest probability based on classic symptoms in low-risk women supports empiric treatment for uncomplicated cystitis, while atypical presentations or complicating factors necessitate referral for comprehensive evaluation to rule out alternative diagnoses or complications. This approach minimizes unnecessary testing while ensuring timely intervention, particularly in vulnerable populations.

Laboratory Tests

Laboratory tests play a central role in confirming the diagnosis of urinary tract infections (UTIs), distinguishing them from other conditions, and guiding appropriate antimicrobial therapy. The primary tests include urinalysis and urine culture, with the latter serving as the gold standard for identifying the causative pathogen and its susceptibility profile. These tests are particularly important in symptomatic patients, where clinical assessment alone may have a diagnostic error rate of up to 33%. Urinalysis begins with a dipstick test, which rapidly detects indicators such as nitrites (produced by nitrate-reducing bacteria like Escherichia coli) and leukocyte esterase (released by white blood cells). Nitrite testing has a specificity exceeding 90% but sensitivity of only 19-48%, while leukocyte esterase shows sensitivity of 62-98% and specificity of 55-96%; combined positive results yield a positive predictive value of 85% and negative predictive value of 92% in symptomatic women. Microscopic examination of urine sediment complements dipstick findings by quantifying white blood cells (>10 per suggests infection) and bacteria, confirming and . Proper specimen collection via midstream clean-catch method is essential to minimize , with samples processed promptly or refrigerated to avoid overgrowth. Urine culture provides definitive microbiologic confirmation, quantifying in colony-forming units per milliliter (CFU/mL). A count of ≥10^5 CFU/mL of a single uropathogen is traditionally diagnostic in symptomatic patients, though thresholds as low as ≥10^3 CFU/mL may suffice in certain contexts, such as catheter-associated UTIs or symptomatic women. Cultures are incubated on media like blood agar and for 24-48 hours, identifying common pathogens such as E. coli (responsible for 75-90% of uncomplicated cases) and assessing susceptibility, which is crucial amid rising resistance patterns. Guidelines recommend cultures for complicated UTIs, recurrent infections, treatment failures, pregnant patients, and men, but not routinely for uncomplicated cystitis in otherwise healthy women where symptoms and may guide empirical therapy. In Germany, the S3-Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei Erwachsenen (AWMF register number 043-044, version 3.0, Stand 09.04.2024, gültig bis 08.04.2029) provides the authoritative national recommendations for diagnosis of uncomplicated cases, aligning with international guidelines in limiting routine urine cultures for uncomplicated cystitis while emphasizing urinalysis and clinical assessment. In cases suggesting systemic involvement, such as , blood tests including (elevated white cells), , and blood cultures may be indicated to evaluate for bacteremia, occurring in 20-30% of upper tract infections. Advanced molecular tests, like PCR for rapid detection, are emerging but not yet standard due to cost and limited availability. Overall, laboratory testing should integrate with clinical findings to optimize diagnostic accuracy and stewardship, reducing unnecessary use.

Imaging and Advanced Diagnostics

Imaging plays a limited role in the initial of uncomplicated urinary tract infections (UTIs), where clinical assessment and tests suffice, but it becomes essential in complicated cases, recurrent infections, or when structural abnormalities, obstructions, or complications such as abscesses are suspected. Guidelines recommend reserving for patients with persistent symptoms after 48-72 hours of appropriate , to respond to treatment, or risk factors like known urolithiasis, , or . This approach helps identify underlying etiologies such as urinary tract obstructions, stones, or perinephric abscesses that may require intervention beyond antimicrobial . Ultrasound is the preferred initial imaging modality due to its non-invasive nature, lack of radiation exposure, and ability to detect , renal abscesses, or outlet obstructions in real-time. In adults with acute or suspected complicated UTI, renal and ultrasound should be performed promptly to exclude obstructions necessitating urgent drainage, particularly within 48 hours of symptom onset. For pregnant patients, is the first-line choice to avoid , with (MRI) considered as an alternative if further evaluation is needed. Limitations include operator dependency and reduced sensitivity for small stones or early parenchymal changes.00837-5/fulltext) Computed tomography (CT) urography, often with contrast, serves as the gold standard for detailed evaluation in complicated UTIs, providing high-resolution images of the kidneys, ureters, , and surrounding structures to identify complications like emphysematous , xanthogranulomatous , or urolithiasis.30940-6/fulltext) It is recommended when findings are inconclusive, symptoms persist beyond 72 hours despite treatment, or in cases of recurrent infections to assess for anatomical anomalies or delayed recovery. Contrast-enhanced CT in the tubulo-interstitial phase (90-120 seconds post-injection) optimizes detection of renal parenchymal involvement. However, its use is judicious due to and contrast risks, particularly in younger patients or those with renal impairment.30940-6/fulltext) MRI, including diffusion-weighted imaging, offers a radiation-free option for complex cases, such as suspected prostatic abscesses or when CT is contraindicated, though it is less commonly used due to higher cost and longer scan times.00837-5/fulltext) In recurrent lower UTI evaluation, MR urography is deemed usually appropriate, especially for women with risk factors like prior pelvic surgery.30940-6/fulltext) Cystoscopy provides direct visualization of the urethra and bladder mucosa and is not routine for acute UTI diagnosis but is indicated in recurrent uncomplicated cystitis (≥3 episodes per year) or complicated cases to identify bladder tumors, stones, diverticula, or interstitial cystitis mimics. It is particularly useful when hematuria persists post-treatment or in patients with suspected anatomical defects contributing to infection persistence. Advanced techniques like blue-light cystoscopy may enhance detection of subtle lesions, though evidence for routine use in UTI remains limited. In pediatric or special populations, imaging thresholds differ; for instance, renal-bladder is recommended after a first febrile UTI in children under 24 months, but adult guidelines emphasize selective use to minimize unnecessary radiation. Overall, a stepwise approach—starting with and escalating to CT or based on clinical response—optimizes diagnostic yield while adhering to evidence-based principles.

Prevention

The prevention of urinary tract infections (UTIs) involves a combination of behavioral and lifestyle modifications, non-antibiotic strategies, and pharmacologic interventions for recurrent cases. The German S3-Leitlinie for uncomplicated bacterial community-acquired urinary tract infections in adults (AWMF register number 043-044, version 3.0, stand 09.04.2024, published September 2024, valid until 08.04.2029) provides comprehensive evidence-based guidance on prevention strategies, among other aspects.

Behavioral and Lifestyle Measures

Behavioral and lifestyle measures play a crucial role in preventing urinary tract infections (UTIs), particularly recurrent uncomplicated cases in women, by reducing bacterial entry into the urinary tract and promoting efficient emptying. These strategies focus on modifiable daily habits that minimize risk factors such as bacterial colonization and urinary stasis, supported by clinical guidelines and observational studies. Hydration is a foundational intervention, with recommendations to increase daily fluid intake to at least 1.5–2 liters of , especially for those consuming less than 1.5 liters previously. This promotes , which flushes bacteria from the and , reducing recurrence rates; in a randomized of premenopausal women, increasing intake from a mean of 1.1 liters to 2.8 liters daily lowered UTI episodes from 3.2 to 1.7 over 12 months. Avoiding irritants like , alcohol, and carbonated beverages further supports this by preventing that could impair urinary flow. Voiding habits are essential to prevent urine retention, which allows bacterial proliferation. Individuals should urinate at regular intervals, ideally every 3–4 hours and whenever the urge arises, while ensuring complete emptying by relaxing and taking sufficient time. Urinating promptly after is particularly important for women, as it expels potentially introduced during activity, thereby decreasing risk. Teaching girls to wipe from front to back after toileting from an early age prevents fecal from reaching the . Personal hygiene practices reduce perineal bacterial load. Taking showers instead of baths minimizes exposure to bathwater contaminants, while avoiding douching, feminine sprays, powders, and harsh soaps preserves the natural that protects against pathogens. For those using contraceptives, switching from spermicide-coated or diaphragm methods to alternatives like intrauterine devices can lower risk, as spermicides disrupt protective barriers. Wearing breathable underwear and loose-fitting clothing prevents moisture buildup that fosters bacterial growth. Additional lifestyle factors include maintaining bowel regularity to avoid , which can impede function, and performing (Kegel) exercises to strengthen muscles that support urinary continence. Regular and weight management contribute indirectly by enhancing overall immune function and reducing obesity-related risks. products, such as juice or tablets, may offer modest benefits by inhibiting bacterial adhesion to uroepithelial cells, though evidence is mixed and they are not universally recommended without approval. In children, probiotics do not treat active UTIs but have been studied for preventing recurrent ones, with some trials suggesting potential benefits while meta-analyses show inconclusive or no significant overall reduction in recurrence risk. Cranberry products may reduce the risk of recurrent UTIs in children, supported by moderate-certainty evidence from systematic reviews.

Prevention in Older Men

Urinary tract infections (UTIs) in men over 70 years are often complicated and strongly associated with underlying prostate issues, particularly benign prostatic hyperplasia (BPH), which causes bladder outlet obstruction, urinary retention, and stasis that promote bacterial proliferation. Complete prevention is challenging without addressing these structural and functional factors. Evidence-based measures include increasing daily fluid intake to flush bacteria from the urinary tract and practicing good genital hygiene to reduce bacterial colonization. Avoiding unnecessary indwelling urinary catheters is critical, as they significantly increase UTI risk; catheters should be used only when clinically indicated, with prompt removal to minimize exposure. Management of underlying BPH is essential to improve urine flow and reduce retention. This may involve alpha-adrenergic blockers (e.g., tamsulosin) or 5-alpha reductase inhibitors (e.g., finasteride) to alleviate obstruction, reduction of bladder irritants such as caffeine and alcohol intake, or surgical interventions like transurethral resection of the prostate (TURP) for severe cases or recurrent UTIs attributable to obstruction. For men with recurrent UTIs, low-dose antibiotic prophylaxis (e.g., nitrofurantoin or trimethoprim for 3–6 months) may be considered after non-pharmacologic measures, guided by prior culture results and local resistance patterns, but requires caution due to the substantial risk of antimicrobial resistance. Non-antibiotic options such as methenamine hippurate may be alternatives. Cranberry products and other non-antimicrobial agents have limited or no strong evidence of efficacy for prevention in older men.

Pharmacologic and Surgical Interventions

Pharmacologic interventions for preventing recurrent urinary tract infections (UTIs) primarily involve prophylaxis and non-antibiotic agents aimed at reducing bacterial and recurrence in at-risk populations, such as women with frequent episodes (>2-3/year). For prevention in frequent recurrences (>2-3/year), consider low-dose antibiotic prophylaxis (using a susceptible agent), post-coital prophylaxis, vaginal estrogen (postmenopausal women), or non-antibiotic strategies (increased hydration, D-mannose, methenamine). Infectious disease consultation is recommended for multidrug-resistant cases. Continuous low-dose antibiotic prophylaxis, using agents to which the pathogen is susceptible (e.g., (50-100 mg daily) or trimethoprim (100 mg daily)), is recommended for 3-12 months in patients with recurrent cystitis after non-pharmacologic measures fail, based on local resistance patterns and culture and susceptibility testing from prior episodes; this approach reduces symptomatic UTIs by approximately 80-90% but carries risks of . Post-coital prophylaxis with single-dose antibiotics, such as trimethoprim-sulfamethoxazole (TMP/SMX) or , is an effective alternative for sexually active women, decreasing UTI incidence by up to 80% in those whose episodes correlate with intercourse. from randomized controlled trials supports these strategies, with strong recommendations from the European Association of (EAU) guidelines (LE 1b). Non-antibiotic pharmacologic options include methenamine hippurate, which acidifies to inhibit and is non-inferior to low-dose antibiotics (1.38 vs. 0.89 episodes per person-year in the multicenter ALTAR trial); as of 2025, UK NHS guidelines recommend it as a first-line alternative to minimize resistance (LE 1b). For postmenopausal women, topical vaginal estrogen (e.g., cream or ) maintains a thick, elastic lining in the vagina, urethra, and bladder resistant to bacterial adhesion; it supports lactobacilli bacteria in the vagina, which produce lactic acid to create a hostile acidic pH against pathogens; postmenopausal decline leads to tissue atrophy, increased pH, and easier bacterial colonization. It restores urogenital and reduces recurrence by 45-65%, with moderate evidence from systematic reviews supporting its use absent contraindications (Grade B). Immunoactive preparations like oral immunostimulants (e.g., OM-89 from extracts) enhance mucosal immunity and decrease recurrences by 30-40% over 6 months, backed by meta-analyses (LE 1a, strong recommendation).
AgentDosage ExampleTarget PopulationEfficacy SummaryEvidence Level
50-100 mg dailyWomen with ≥3 UTIs/yearReduces episodes by 85%LE 1b (EAU)
TMP/SMX (post-coital)40/200 mg single doseSexually active women80% reduction post-intercourseGrade B (AUA)
Methenamine hippurate1 g twice dailyRecurrent cystitis patientsNon-inferior to antibiotics (1.38 vs. 0.89 episodes/person-year)LE 1b (EAU)
Vaginal estrogen0.5 mg 3x/weekPostmenopausal women50% risk reductionGrade B (AUA)
OM-891 tablet daily for 3 monthsAdults with recurrent UTIs36% recurrence reductionLE 1a (EAU)
Surgical interventions are reserved for recurrent UTIs attributable to correctable anatomical or functional abnormalities, such as urinary obstruction, , or calculi, rather than as routine prophylaxis. Procedures like (TURP) for bladder outlet obstruction or ureteral reimplantation for high-grade in adults can eliminate stasis and reduce infection risk, with success rates supported by cohort studies and EAU guidelines. Removal of infected stones via (PCNL) or shockwave addresses nidus formation, preventing recurrence per systematic reviews. For urethral strictures or diverticula, or diverticulectomy improves drainage and yields resolution of UTIs, though evidence is primarily from observational data (Level 3); success ~50% for . In select cases of neurogenic , sacral interrupts dysfunctional voiding patterns, achieving 60-70% UTI reduction in trials. These interventions prioritize source control, with decisions guided by imaging and urologic evaluation per AUA and EAU recommendations.

Treatment

Uncomplicated Urinary Tract Infections

Uncomplicated urinary tract infections (UTIs), also known as acute uncomplicated cystitis, refer to bacterial infections confined to the lower urinary tract (bladder) in otherwise healthy, premenopausal, non-pregnant women without structural or functional abnormalities of the urinary tract or significant comorbidities. These infections are typically caused by uropathogenic Escherichia coli and present with symptoms such as dysuria, urinary frequency, urgency, and suprapubic pain, without systemic signs like fever or flank pain that would suggest upper tract involvement. Treatment focuses on short-course oral antibiotics to achieve rapid symptom resolution, minimize resistance development, and reduce recurrence risk, guided by local antimicrobial susceptibility patterns. Antibiotics remain the mainstay of therapy, tailored to urine culture results and local resistance patterns when available; common options include trimethoprim-sulfamethoxazole (Bactrim), nitrofurantoin, ciprofloxacin or other fluoroquinolones, and cephalexin. Patients should complete the full prescribed course even if symptoms improve early to fully eradicate the infection and prevent resistance or recurrence. In Germany, the current authoritative guideline for the epidemiology, diagnosis, therapy, prevention, and management of uncomplicated bacterial, community-acquired urinary tract infections in adults is the S3-Leitlinie (AWMF register number 043-044, version 3.0, dated 09.04.2024, valid until 08.04.2029, with the long version published in September 2024). A separate S3 guideline for complicated urinary tract infections (AWMF 043-060) is registered but has not yet been published. First-line antibiotic therapy for uncomplicated cystitis emphasizes agents with high efficacy, low resistance rates, and favorable safety profiles. (100 mg orally twice daily for 5 days) is a preferred option due to its concentrated urinary excretion and low systemic absorption, achieving clinical success rates of approximately 90% in susceptible isolates. Trimethoprim-sulfamethoxazole (160/800 mg orally twice daily for 3 days) is another first-line choice when local E. coli resistance is below 20%, with similar high cure rates but increased risk of adverse effects like in susceptible patients. Fosfomycin (3 g as a single oral dose) offers a convenient alternative, particularly for multidrug-resistant strains, with efficacy around 85-90% and minimal impact on . In regions where available, (400 mg orally three times daily for 3-5 days), approved by the FDA in 2024, provides effective coverage against resistant E. coli and other , with clinical success rates of 70-82%. (1,500 mg orally three times daily for 5 days), approved by the FDA in March 2025, is a novel triazaacenaphthylene , the first new class in nearly 30 years, effective for uncomplicated UTIs in females aged 12 years and older, with clinical success rates of approximately 50-60% in phase 3 trials against resistant strains.
AntibioticDosage and DurationKey ConsiderationsEfficacy (Approximate Clinical Success Rate)
100 mg PO BID × 5 daysAvoid in or CrCl <30 mL/min; low resistance90%
TMP-SMX160/800 mg PO BID × 3 daysUse only if resistance <20%; monitor for sulfa allergy90-93%
Fosfomycin3 g PO single dosePreferred for resistance or pregnancy; single-dose convenience85-91%
Pivmecillinam400 mg PO TID × 3-5 daysEffective vs. resistant strains; approved 202470-82%
Gepotidacin1,500 mg PO TID × 5 daysNovel class for resistant strains; approved March 2025; for females ≥12 years50-60%
Second-line agents, such as oral fluoroquinolones (e.g., ciprofloxacin 250 mg twice daily for 3 days), are reserved for cases of allergy, intolerance, or high local resistance to first-line options, due to concerns over collateral damage including Clostridium difficile infection and broader resistance emergence. Beta-lactams like amoxicillin-clavulanate or first-generation cephalosporins (e.g., cephalexin 250 mg four times daily for 3-7 days) have lower efficacy (70-80%) and higher relapse rates, making them less preferred unless other options are unavailable. Treatment duration is generally short (3-5 days) to optimize adherence and reduce selective pressure for resistance, with symptom improvement expected within 48-72 hours; persistent symptoms warrant urine culture and susceptibility testing to guide adjustments. In men, uncomplicated UTIs are rare and typically managed as complicated infections with a 7-day course of agents such as trimethoprim-sulfamethoxazole or a fluoroquinolone, guided by susceptibility testing. For pregnant women, uncomplicated cystitis treatment prioritizes nitrofurantoin (avoid in late pregnancy) or cephalexin to prevent ascending infection, with screening and prophylaxis as needed. Non-antibiotic strategies, such as increased fluid intake or D-mannose supplementation, may adjunct therapy but lack sufficient evidence as monotherapy for acute episodes. Overall, antimicrobial stewardship emphasizes urine culture prior to therapy only in recurrent or treatment-failure cases, promoting targeted use to combat rising multidrug resistance.

Complicated Urinary Tract Infections

Complicated urinary tract infections (cUTIs) are defined as infections occurring in the presence of structural or functional abnormalities of the urinary tract, such as urinary obstruction, vesicoureteral reflux, indwelling catheters, or in patients with compromised host defenses, including those with diabetes, immunosuppression, or renal transplantation. These infections often involve the upper urinary tract or lead to systemic symptoms like fever and flank pain, distinguishing them from uncomplicated cases. Management of cUTIs begins with prompt evaluation, including collection of a high-quality urine sample for urinalysis, microscopy, and culture prior to initiating antibiotics to guide targeted therapy. Imaging, such as renal ultrasound or computed tomography, is recommended if there is suspicion of obstruction, abscess, or nephrolithiasis, particularly in patients with persistent fever or sepsis beyond 48-72 hours of treatment. Hospitalization is warranted for severe cases involving sepsis, hemodynamic instability, or inability to tolerate oral medications. Empiric antibiotic therapy should be broad-spectrum to cover common pathogens like Escherichia coli, Klebsiella species, and Enterococcus, while considering local resistance patterns and patient-specific risk factors such as prior antibiotic exposure or hospitalization. For non-septic patients, preferred oral or intravenous options include fluoroquinolones (e.g., ciprofloxacin 500-750 mg twice daily or levofloxacin 750 mg once daily), third- or fourth-generation cephalosporins (e.g., ceftriaxone 2 g intravenously once daily), or piperacillin-tazobactam (4.5 g intravenously every 6 hours). In septic patients, recommendations favor intravenous third- or fourth-generation cephalosporins, carbapenems (e.g., ertapenem 1 g daily), or piperacillin-tazobactam, with the addition of an aminoglycoside (e.g., gentamicin 5-7 mg/kg daily) if high-risk features like multidrug-resistant organisms are suspected. Therapy is de-escalated to narrow-spectrum agents based on culture susceptibilities, typically within 48-72 hours. A stepwise approach to antibiotic selection is advised: first assess clinical severity, then evaluate resistance risks (e.g., extended-spectrum beta-lactamase producers), followed by patient comorbidities, and finally local antibiograms. Transition from intravenous to oral antibiotics is recommended once the patient is clinically stable, afebrile for 48 hours, able to tolerate oral intake, and an effective oral agent is available, often shortening overall hospital stays. For multidrug-resistant infections, newer agents like ceftazidime-avibactam or cefiderocol may be considered in consultation with infectious disease specialists. Treatment duration for most cUTIs is 7-14 days, with shorter courses of 5-7 days possible for fluoroquinolone-based regimens in clinically improving patients without bacteremia. For cases with bacteremia or upper tract involvement, 7-10 days is standard, extending to 14 days in males with complicating factors or delayed response. Longer durations of 14-21 days are required for specific scenarios, such as renal transplant recipients or perinephric abscesses, while prostatitis may necessitate 4-6 weeks. For recurrent complicated urinary tract infections, particularly those caused by Klebsiella pneumoniae or multidrug-resistant pathogens, each episode requires urine culture and susceptibility testing to guide targeted antibiotic selection. Acute episodes are treated with pathogen-specific antibiotics, such as nitrofurantoin or fosfomycin for susceptible strains, or carbapenems, fluoroquinolones (if susceptible), or agents like ceftazidime-avibactam for resistant, ESBL-producing, or carbapenem-resistant strains. Underlying causes (e.g., urinary tract obstruction, stones, indwelling catheters, diabetes) should be investigated with imaging or urology referral. Infectious disease consultation is recommended for multidrug-resistant cases. For patients with frequent recurrences (>2-3 episodes per year), preventive strategies may include low-dose antibiotic prophylaxis with a susceptible agent, post-coital prophylaxis in sexually active individuals, vaginal estrogen in postmenopausal women, or non-antibiotic approaches such as increased hydration, D-mannose, or methenamine. Key management strategies include addressing underlying risk factors to prevent recurrence, such as relieving urinary obstruction via stenting or nephrostomy, removing or replacing indwelling catheters (e.g., with silver-alloy coated devices to reduce biofilm formation), and ensuring adequate bladder drainage in septic patients. In catheter-associated cUTIs, catheter exchange combined with a 5-7 day course of antibiotics like levofloxacin is effective for non-severely ill patients. For pregnant patients, beta-lactams (e.g., amoxicillin-clavulanate) or fosfomycin are preferred, with treatment extended to cover asymptomatic bacteriuria. Dose adjustments are essential in renal impairment, avoiding agents like nitrofurantoin if creatinine clearance is below 60 mL/min. Follow-up urine cultures and clinical reassessment within 48-72 hours are crucial for outpatients to confirm response and detect treatment failure.

Pyelonephritis and Upper Tract Infections

Pyelonephritis is a bacterial infection involving the renal pelvis and parenchyma, typically resulting from ascending spread of pathogens from the lower urinary tract, most commonly Escherichia coli. Upper tract infections encompass pyelonephritis and related conditions such as renal abscesses, which can lead to systemic complications if untreated. Treatment focuses on empirical antibiotic therapy guided by local resistance patterns, with decisions on outpatient versus inpatient management based on severity, comorbidities, and patient stability. For acute uncomplicated pyelonephritis in otherwise healthy, non-pregnant women, outpatient oral therapy is often appropriate if the patient can tolerate medications and has no signs of sepsis or dehydration. Recommended regimens include ciprofloxacin 500 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days, provided local fluoroquinolone resistance is below 10%. Trimethoprim-sulfamethoxazole (160/800 mg twice daily for 14 days) serves as an alternative if regional resistance is less than 20% and the patient has no sulfa allergy. Oral beta-lactams, such as amoxicillin-clavulanate 875 mg twice daily for 14 days, may be used when fluoroquinolones are contraindicated, though they are less effective and associated with higher relapse rates. An initial single dose of intravenous ceftriaxone (1 g) can be considered for severe symptoms before transitioning to oral agents. In complicated pyelonephritis—such as cases involving urinary tract obstruction, immunosuppression, pregnancy, or indwelling catheters—initial intravenous antibiotics are typically required, especially if sepsis is present. Preferred agents include third- or fourth-generation cephalosporins (e.g., ceftriaxone 1-2 g daily), piperacillin-tazobactam (3.375-4.5 g every 6 hours), or carbapenems (e.g., ertapenem 1 g daily) for broad coverage against gram-negative pathogens. Fluoroquinolones (e.g., ciprofloxacin 400 mg IV every 12 hours) are alternatives if resistance risk is low, but should be avoided in patients with recent fluoroquinolone exposure due to rising resistance. Therapy duration is generally 7-14 days total, with a switch to oral equivalents once the patient is clinically stable, afebrile for 48 hours, and able to tolerate oral intake; shorter courses of 5-7 days with fluoroquinolones suffice for improving patients without bacteremia. Hospitalization is indicated for patients with high fever (>39°C), persistent , hemodynamic instability, suspected urinary obstruction, or significant comorbidities, where parenteral therapy can be administered until improvement, typically within 72 hours. Supportive measures include hydration, antipyretics (e.g., acetaminophen), and analgesics (e.g., nonsteroidal drugs for flank ), but these do not replace antibiotics. In pregnant individuals, safe options include intravenous cefepime or followed by oral cephalexin for a total of 14 days, avoiding fluoroquinolones and trimethoprim due to teratogenic risks. culture and susceptibility testing should guide de-escalation, with follow-up cultures recommended 1-2 weeks post-treatment in complicated cases to confirm resolution. Imaging, such as or CT, may be pursued if response is poor to rule out or obstruction.

Management in Special Populations

Management of urinary tract infections (UTIs) in pregnant individuals requires prompt screening and treatment due to risks of preterm labor and . All pregnant individuals should be screened for asymptomatic (ASB) at 12-16 weeks using urine culture, with treatment recommended for positive results to prevent complications. For acute cystitis, first-line oral antibiotics include 100 mg twice daily for 5-7 days or cephalexin 500 mg twice daily for 3-7 days; amoxicillin is an alternative if susceptible. Fluoroquinolones and trimethoprim-sulfamethoxazole are avoided, especially in the first trimester, due to teratogenic risks. In cases of , initial hospitalization with intravenous antibiotics such as or is advised, transitioning to oral therapy once stable, with a total duration of 10-14 days. Follow-up cultures are essential post-treatment to confirm clearance. In pediatric patients, UTI management varies by age, clinical presentation, and risk factors for . Prompt initiation of antibiotics is essential, particularly for febrile UTIs, as delays in treatment are associated with increased risk of renal scarring. For febrile infants under 2 months, hospitalization and intravenous antibiotics (e.g., plus gentamicin or ) are recommended until afebrile, followed by oral therapy for a total of 7-14 days. Children over 2 months with cystitis may receive oral trimethoprim-sulfamethoxazole or amoxicillin-clavulanate for 3-5 days if non-febrile, while febrile upper tract infections warrant 7-10 days of therapy. , such as renal , is indicated after the first febrile UTI in children under 2 years to assess for abnormalities. Prophylactic antibiotics like trimethoprim are considered for recurrent febrile UTIs or high-grade reflux, though recent evidence questions routine use due to limited benefit in preventing renal scarring. Elderly patients often present with atypical symptoms like or incontinence, and UTIs are frequently complicated by comorbidities such as or catheterization, necessitating urine culture-guided therapy. Short-course antibiotics (3-7 days) of or trimethoprim-sulfamethoxazole are effective for uncomplicated lower UTIs, but durations extend to 10-14 days for or bacteremia. Asymptomatic bacteriuria should not be treated unless in specific contexts like pre-urologic procedures, to avoid promoting resistance. Cranberry products or methenamine hippurate may aid prevention in recurrent cases, particularly in settings. Multidisciplinary assessment addresses underlying factors like mobility issues or incontinence. In men, UTIs are inherently complicated due to prostatic involvement, requiring longer courses of 7-14 days with agents like or levofloxacin for susceptible pathogens, or beta-lactams if resistance is suspected. Evaluation for structural abnormalities, such as prostatic , is crucial, often involving post-void residual measurement or referral. For acute bacterial prostatitis complicating UTI, extended therapy (4-6 weeks) with fluoroquinolones is standard. Recurrent infections may indicate , managed with low-dose prophylaxis. Immunocompromised patients, including those with , transplant recipients, or , face higher risks of severe or recurrent UTIs, treated as complicated infections with broad-spectrum intravenous antibiotics initially (e.g., piperacillin-tazobactam or ) for 7-14 days, guided by culture sensitivities. generally warrants no treatment except in renal transplant patients within the first month post-transplant or before invasive procedures. Prophylaxis with trimethoprim-sulfamethoxazole is considered in high-risk groups like neutropenic patients during . Close monitoring for resistance, particularly to extended-spectrum producers, is essential.

Prognosis and Complications

Prognosis

The prognosis of urinary tract infections (UTIs) is generally favorable with prompt and appropriate treatment, particularly for uncomplicated cases in otherwise healthy individuals. In uncomplicated UTIs, symptoms typically resolve within 2 to 4 days of antibiotic therapy, with near-zero mortality rates. Approximately 20% of cases may resolve spontaneously with increased fluid intake and supportive care, though antibiotic treatment is recommended to prevent progression. Recurrence is common, affecting about 30% of patients within 6 months and up to 50% within a year, with higher risks in women due to anatomical factors. For complicated UTIs, which occur in patients with underlying conditions such as , urinary tract obstructions, or indwelling catheters, the prognosis is more guarded due to increased risks of treatment and systemic spread. Clinical recovery is achieved in approximately 95% of cases with targeted antibiotics and supportive interventions, though in-hospital mortality can reach 4% in severe presentations. Without , mortality remains low at 5% or less; however, elevates this risk to over 10%, and can exceed 40%. Early transition from intravenous to oral antibiotics and shorter courses (5-7 days) improve outcomes by reducing adverse events and recurrence while maintaining efficacy. Untreated UTIs, regardless of type, carry a poorer and can lead to serious complications such as , renal abscesses, or , potentially resulting in permanent damage or chronic renal impairment. In specific populations, such as renal transplant recipients, UTIs contribute to graft dysfunction, though overall mortality has declined to less than 5% with modern . Long-term effects include persistent and increased antibiotic resistance, underscoring the importance of timely intervention and addressing risk factors like recurrent infections or structural abnormalities.

Complications

Untreated or recurrent urinary tract infections (UTIs) can lead to a range of serious complications, particularly when the infection ascends to the upper urinary tract or becomes systemic. The most common acute complication is , an infection of the s that occurs when bacteria from a lower UTI spread upward, causing fever, flank pain, and potential permanent kidney damage if not promptly treated. In complicated UTIs—those involving structural abnormalities, catheters, or immunocompromised states— can progress to formation, such as perinephric abscesses, which may require surgical drainage if antibiotics alone fail. Systemic spread represents a life-threatening escalation, with untreated kidney infections potentially leading to or urosepsis, a condition where bacteria enter the bloodstream and trigger widespread . from UTIs carries a mortality risk of up to 10% in cases of urinary tract-related bacteremia, particularly in vulnerable populations like the elderly or those with . Abscesses or obstructions can further exacerbate this by promoting bacterial proliferation and toxin release, contributing to if not addressed within 48-72 hours of initiating treatment. Long-term consequences are more pronounced in recurrent or childhood UTIs, including , , and end-stage renal disease due to scarring and impaired renal function from repeated inflammation and bacterial toxins like α-hemolysin. In young children, renal damage from can manifest years later as reduced kidney function, with studies linking early infections to a higher incidence of in adulthood. For men, repeated infections may cause urethral strictures through scarring, leading to urinary obstruction and further infection cycles. In pregnancy, UTIs heighten risks of preterm labor, low birthweight infants, and maternal , necessitating routine screening to prevent ascent to the kidneys. Globally, complications contribute to significant morbidity, with UTIs accounting for over 1 million emergency visits annually in the and societal costs exceeding $3.5 billion, largely driven by and renal sequelae. Prompt antibiotic therapy mitigates most risks, but delays in or treatment in high-risk groups amplify the potential for irreversible harm.

Background

Epidemiology

Urinary tract infections (UTIs) represent a significant burden, affecting over 4.49 billion people with incident cases in 2021, marking a 66.45% increase from levels. The age-standardized incidence rate (ASIR) rose from 5,294.5 to 5,531.88 per 100,000 population over this period, with projections estimating a further 43.50% rise in cases by 2050, reaching an ASIR of 6,486.39 per 100,000. In 2019, UTIs resulted in approximately 404.6 million prevalent cases worldwide, 236,786 deaths, and 5.2 million disability-adjusted life years (DALYs), underscoring their role as one of the most common bacterial infections. The lifetime probability of developing a UTI stands at 93.70% globally, with females facing a higher of 96.05% compared to 77.27% in males. UTIs disproportionately affect females, with women experiencing roughly four times the ASIR of men due to anatomical factors such as a shorter . In premenopausal women, the lifetime incidence reaches 50-60%, with uncomplicated cystitis occurring at a rate of about 0.5 episodes per person-year among sexually active young . Among postmenopausal women, annual prevalence is around 10%, escalating to 20% in those over 65 years. Among men with acute UTIs, the prevalence of recurrence is about 15.7% in some studies, with overall incidence peaking after age 80. Children and individuals are also vulnerable; for instance, UTI prevalence during is approximately 18% in U.S. cohorts. In healthcare settings, UTIs account for over 30% of hospital-acquired infections, with catheter-associated cases comprising 75% of nosocomial UTIs and affecting up to 15-25% of catheterized patients. Key risk factors include prior UTI history, sexual activity, , , urinary tract obstructions, and catheterization, particularly in older adults and facilities where 12-month incidence rates reach 19.8% in women and 6.4% in men. Regionally, the highest ASIR occurs in tropical (13,021.38 per 100,000), while bears the largest absolute case burden at over 242 million in 2021. exacerbates the issue, contributing to 287,200 UTI-related deaths in 2021, with greater impacts in low- to middle-socio-demographic index regions.

History

Urinary tract infections (UTIs) have been recognized since ancient times, with the earliest documented descriptions appearing in the from around 1550 BC, which detailed urinary symptoms such as painful urination and recommended palliative remedies including mixtures of honey, beer, and plants to alleviate discomfort without understanding the underlying . In , (c. 460–370 BC) attributed urinary disorders, including those resembling UTIs, to imbalances in the four humors—blood, phlegm, yellow bile, and black bile—leading to symptomatic treatments focused on restoring equilibrium through diet and purgatives. Roman physicians like (c. 25 BC–50 AD) advanced management by advocating , light diets, analgesics, and infusions, while also refining surgical techniques such as catheterization and for associated complications like stones or retention. During the Middle Ages, progress stalled, but Arabian physicians such as Aetius of Amida (6th century AD) refined uroscopy—the examination of urine color, sediment, and odor—as a diagnostic tool and classified urinary diseases, including urethritis often caused by gonorrhea, which was treated with topical astringents and dietary restrictions. By the 19th century, clinicians provided vivid clinical descriptions of UTIs, such as suppurative pyelonephritis documented by Billroth in 1874, yet the microbial etiology remained unrecognized despite the broader germ theory advancements by Pasteur and Koch in the 1860s–1880s. Pre-antibiotic treatments were palliative, emphasizing hospitalization, bed rest, opioid narcotics, herbal douches and enemas, bloodletting via leeches or cupping, and surgical interventions for abscesses or obstructions, as the bacterial cause of most UTIs was not established until the early 20th century when pathogens like Escherichia coli were consistently isolated from infected urine. The 20th century revolutionized UTI with the advent of antimicrobial agents, beginning with sulfonamides in the 1930s, which were the first systemic drugs effective against common UTI pathogens like E. coli and marked a shift from supportive care to . Penicillin, discovered in 1928 and widely available by the 1940s, had limited utility against predominant in UTIs, prompting the development of broader-spectrum options. , introduced in 1953, became the first truly effective and safe antibiotic specifically for lower UTIs due to its concentration in urine and activity against common uropathogens, significantly reducing morbidity and mortality. Subsequent milestones included amoxicillin in the , which faced rapid resistance, leading to trimethoprim-sulfamethoxazole (TMP-SMX) as a first-line agent until resistance emerged, and fluoroquinolones in the 1980s, which offered empirical coverage but raised concerns over collateral resistance and side effects. These developments transformed UTIs from potentially life-threatening conditions, especially in complicated cases, into largely treatable infections, though ongoing challenges like continue to evolve strategies.

In Veterinary Medicine

In Companion Animals

Urinary tract infections (UTIs) are a prevalent condition in companion animals, particularly dogs and cats, where they represent one of the most common reasons for antimicrobial prescriptions in veterinary practice. In dogs, the lifetime prevalence of UTIs is approximately 14%, while in cats it ranges from 1% to 8%, with higher rates observed in females due to their shorter urethras and in older animals associated with comorbidities such as diabetes mellitus or chronic kidney disease. Bacterial cystitis, the most frequent form, often involves ascending infection from the lower genital tract, though subclinical bacteriuria—bacteria in the urine without clinical signs—occurs in cats with idiopathic cystitis. The primary pathogens responsible for UTIs in companion animals are gram-negative bacteria, with Escherichia coli accounting for 33–51% of cases in both dogs and cats, followed by Staphylococcus spp., Proteus spp., Enterococcus spp., and Klebsiella spp. In dogs, Escherichia coli is the most common bacterial cause of urinary tract infections. Risk factors include anatomical abnormalities like urolithiasis, urinary catheterization, immunosuppression, and conditions promoting urine stasis such as obesity or prostatic disease in intact male dogs. Clinical signs typically include pollakiuria, dysuria, hematuria, and stranguria, though upper tract involvement (pyelonephritis) may present with systemic signs like fever, lethargy, and vomiting. In cats, UTIs are less common in young animals but increase with age, often linked to feline lower urinary tract disease. Diagnosis relies on a combination of history, , showing and , and quantitative aerobic urine culture, ideally obtained via cystocentesis to avoid contamination, with bacterial counts ≥10³ colony-forming units/mL considered significant. UTIs are classified as sporadic (simple, uncomplicated cystitis with <3 episodes per year), complicated (with underlying structural or functional issues), or recurrent (reinfection or ). Subclinical generally does not warrant treatment unless associated with risks like or . Imaging such as may be used to identify predisposing factors like calculi. Treatment follows culture and susceptibility testing to guide selection, emphasizing to combat rising resistance. For sporadic bacterial cystitis in dogs and cats, first-line options include amoxicillin (11–15 mg/kg PO q8–12h) or trimethoprim-sulfamethoxazole (15–30 mg/kg PO q12h) for 3–5 days, with fluoroquinolones like (5–20 mg/kg PO q24h) reserved for complicated cases or due to resistance concerns. Complicated UTIs or require 10–14 days or longer (up to 4–6 weeks for ), often with amoxicillin-clavulanate or , and addressing underlying causes such as surgical removal of uroliths or in males. is notable, with E. coli showing 36–62% resistance to amoxicillin and quinolones in recent , though trends indicate declines in some agents post-2019 due to regulatory restrictions. Prevention focuses on managing risk factors rather than routine prophylaxis, as evidence does not support long-term low-dose antimicrobials, extracts, or , which may promote resistance. Dietary modifications to acidify urine or dissolve uroliths, along with increased water intake to promote dilute urine, are recommended for at-risk animals. is generally favorable with prompt treatment, though recurrent infections necessitate thorough investigation to prevent complications like or .

In Livestock and Wildlife

Urinary tract infections (UTIs) in livestock are typically ascending bacterial infections that often arise secondary to predisposing factors such as parturition, urolithiasis, trauma, or impaired urine flow, leading to cystitis, pyelonephritis, or more severe complications like renal failure. These infections are economically significant in production animals, contributing to reduced productivity, culling, and mortality, with prevalence varying by species and management practices. Common pathogens include Escherichia coli, Corynebacterium renale, and species-specific bacteria, often requiring culture-guided antimicrobial therapy. In , bovine cystitis and are characterized by inflammation of the and kidneys, primarily affecting cows post-calving due to trauma or stress, with a herd-level prevalence of less than 1–2%. Clinical signs include , stranguria, pollakiuria, fever, and , progressing to chronic and if untreated. Diagnosis involves showing , , and , confirmed by bacterial culture; treatment entails prolonged antibiotics like penicillin or for 2–4 weeks, with supportive care including fluid therapy and isolation of affected animals. Porcine cystitis-pyelonephritis complex is a leading cause of sow mortality, driven mainly by Actinobaculum suis, an anaerobic gram-positive bacterium, alongside opportunistic pathogens like E. coli and Streptococcus spp. Risk factors include poor hygiene, limited water access, obesity, and leg lameness, with infections manifesting as acute sudden death from uremia or chronic signs such as hematuria, pyuria, and ammonia-scented urine. Diagnostic confirmation requires anaerobic culture or PCR on urine samples; effective treatments include penicillin or ampicillin for 3–5 days, combined with urine acidification using citric acid to prevent struvite crystal formation. Prevention emphasizes sanitation, adequate watering, and culling sows after high parity. In small ruminants like sheep and goats, UTIs are less common but frequently secondary to obstructive urolithiasis, posthitis, or vulvitis, particularly in males due to urethral anatomy. Pathogens such as E. coli and Corynebacterium spp predominate, with clinical features including dysuria, hematuria, and systemic illness if ascending to pyelonephritis. Management involves addressing underlying obstructions via catheterization or surgery, followed by antibiotics like ceftiofur or penicillin based on culture results; vulvitis in females may require topical antiseptics. Horses experience UTIs predominantly as complications of bladder atony, urolithiasis, or catheterization, with E. coli, , and spp as key isolates. Symptoms encompass stranguria, incontinence, and ; diagnosis relies on and culture, while treatment uses systemic antibiotics such as penicillin G or for extended courses, often with urinary acidifiers. improves with early intervention to restore normal micturition. In , UTIs are rarely documented in free-ranging populations due to limited , but cases have been noted in captive or managed exotic species, such as , where they occur secondary to neurological deficits or trauma leading to and secondary bacterial ascension. Pathogens mirror those in domestic ruminants, and management in zoological settings follows similar protocols adapted for conservation concerns.

References

  1. https://www.cdc.gov/uti/about/index.html
  2. https://www.mayoclinic.org/diseases-conditions/urinary-tract-infection/symptoms-causes/syc-20353447
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6502976/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4457377/
  5. https://www.cdc.gov/infection-control/hcp/cauti/background.html
  6. https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults
  7. https://pubmed.ncbi.nlm.nih.gov/12113866/
  8. https://www.mayoclinic.org/diseases-conditions/urinary-tract-infection/diagnosis-treatment/drc-20353453
  9. https://www.ncbi.nlm.nih.gov/books/NBK470195/
  10. https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/definition-facts
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10145414/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC1071654/
  13. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/
  14. https://uroweb.org/guidelines/urological-infections
  15. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1402941/full
  16. https://www.merckmanuals.com/professional/genitourinary-disorders/urinary-tract-infections-utis/fungal-urinary-tract-infections
  17. https://my.clevelandclinic.org/health/diseases/9135-urinary-tract-infections
  18. https://www.yalemedicine.org/conditions/enlarged-prostate-benign-prostatic-hyperplasia-bph
  19. https://www.health.harvard.edu/mens-health/the-growing-problem-of-an-enlarged-prostate-gland
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6502981/
  21. https://www.yalemedicine.org/conditions/urinary-tract-infection
  22. https://www.nejm.org/doi/full/10.1056/NEJM199309093291102
  23. https://www.ncbi.nlm.nih.gov/books/NBK559297/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7942789/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC5159206/
  26. https://doi.org/10.1038/nm1419
  27. https://doi.org/10.1038/nm1552
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC4504509/
  29. https://doi.org/10.3389/fmed.2022.931717
  30. https://doi.org/10.1371/journal.ppat.1005044
  31. https://doi.org/10.1038/s41579-020-0324-0
  32. https://pubmed.ncbi.nlm.nih.gov/23455496/
  33. https://www.hopkinsmedicine.org/health/conditions-and-diseases/urinary-tract-infections
  34. https://medlineplus.gov/urinarytractinfections.html
  35. https://www.aafp.org/pubs/afp/issues/2015/1101/p778.html
  36. https://www.merckmanuals.com/professional/genitourinary-disorders/symptoms-of-genitourinary-disorders/dysuria
  37. https://www.mayoclinic.org/diseases-conditions/kidney-stones/symptoms-causes/syc-20355755
  38. https://my.clevelandclinic.org/health/diseases/15604-kidney-stones
  39. https://www.webmd.com/kidney-stones/understanding-kidney-stones-symptoms
  40. https://www.niddk.nih.gov/health-information/urologic-diseases/urinary-tract-infections-in-children/symptoms-causes
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC5873814/
  42. https://www.nichd.nih.gov/health/topics/urinary/conditioninfo/symptoms
  43. https://www.ncbi.nlm.nih.gov/books/NBK537047/
  44. https://www.ncbi.nlm.nih.gov/books/NBK436013/
  45. https://pubmed.ncbi.nlm.nih.gov/18519018/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5582677/
  47. https://nortonhealthcare.com/news/uti-or-kidney-stone/
  48. https://atlanticurologyclinics.com/blog/kidney-stone-vs-uti-how-to-tell/
  49. https://www.ncbi.nlm.nih.gov/books/NBK557569/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC2883276/
  51. https://register.awmf.org/de/leitlinien/detail/043-044
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC8994576/
  53. https://pubmed.ncbi.nlm.nih.gov/36192024/
  54. https://uroweb.org/guidelines/urological-infections/chapter/the-guideline
  55. https://www.sciencedirect.com/science/article/pii/S221156841200126X
  56. https://www.auanet.org/documents/education/NMSC-Adult-UTI.pdf
  57. https://www.auanet.org/guidelines-and-quality/guidelines/recurrent-uti
  58. https://www.ncbi.nlm.nih.gov/books/NBK557479/
  59. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2705079
  60. https://www.nia.nih.gov/health/bladder-health-and-incontinence/15-tips-keep-your-bladder-healthy
  61. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008772.pub2/full
  62. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001321.pub7/full
  63. https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
  64. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825634
  65. https://www.bmj.com/content/376/bmj-2021-0068229
  66. https://www.newcastle-hospitals.nhs.uk/news/results-of-clinical-trial-prompt-changes-to-nhs-guidelines-for-recurrent-urinary-tract-infections/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC5522803/
  68. https://www.idsociety.org/news--publications-new/articles/2025/idsa-releases-new-guidelines-for-management-and-treatment-of-complicated-urinary-tract-infections/
  69. https://www.idsociety.org/practice-guideline/urinary-tract-infection/
  70. https://www.ajkd.org/article/S0272-6386%2823%2900837-5/fulltext
  71. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections
  72. https://www.ajmc.com/view/fda-approves-first-new-class-of-oral-antibiotics-for-uncomplicated-utis-in-nearly-30-years
  73. https://www.uptodate.com/contents/acute-complicated-urinary-tract-infection-including-pyelonephritis-in-adults
  74. https://www.ncbi.nlm.nih.gov/books/NBK519537/
  75. https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-uti/
  76. https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/08/urinary-tract-infections-in-pregnant-individuals
  77. https://pubmed.ncbi.nlm.nih.gov/27455161/
  78. https://publications.aap.org/pediatrics/article/128/3/595/30724/Urinary-Trajectory-Infection-Clinical-Practice
  79. https://www.ncbi.nlm.nih.gov/books/NBK599548/
  80. https://publications.aap.org/pediatrics/article/147/2/e2020012138/36243/Contemporary-Management-of-Urinary-Tract-Infection
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC3131987/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC8170603/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC10678746/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC9484510/
  85. https://pubmed.ncbi.nlm.nih.gov/10578498/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC8931190/
  87. https://www.nature.com/articles/s41598-025-89240-5
  88. https://link.springer.com/article/10.1007/s00345-021-03913-0
  89. https://jhpn.biomedcentral.com/articles/10.1186/s41043-025-00950-y
  90. https://stacks.cdc.gov/view/cdc/115866
  91. https://www.cdc.gov/uti/hcp/clinical-safety/index.html
  92. https://www.sciencedirect.com/science/article/abs/pii/S1047279725000365
  93. https://www.auajournals.org/doi/10.1097/01.ju.0000141496.59533.b2
  94. https://pubmed.ncbi.nlm.nih.gov/15592019/
  95. https://www.ncbi.nlm.nih.gov/books/NBK470526/
  96. https://www.merckvetmanual.com/urinary-system/infectious-diseases-of-the-urinary-system-in-small-animals/bacterial-cystitis-in-small-animals
  97. https://www.mdpi.com/2076-2607/12/11/2175
  98. https://avmajournals.avma.org/view/journals/javma/aop/javma.25.05.0314/javma.25.05.0314.xml
  99. https://www.vdl.ndsu.edu/wp-content/uploads/2022/02/ISCAID-Urinary-Guidelines-2019.pdf
  100. https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-urinary-system/pharmacotherapeutics-in-bacterial-urinary-tract-infections-in-animals
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC12474177/
  102. https://www.merckvetmanual.com/urinary-system/infectious-diseases-of-the-urinary-system-in-large-animals/bovine-cystitis-and-pyelonephritis
  103. https://www.merckvetmanual.com/urinary-system/infectious-diseases-of-the-urinary-system-in-large-animals/porcine-cystitis-pyelonephritis-complex
  104. https://pubmed.ncbi.nlm.nih.gov/33358314/
  105. https://pubmed.ncbi.nlm.nih.gov/16882485/
Add your contribution
Related Hubs
User Avatar
No comments yet.